

## POSTER SESSION

Posters will be charged into the platform at disposal for all participant. Authors will have at disposal a 3-minutes recording speech to be integrated to the poster file.

### PATHOGENESIS (AUTOANTIBODIES)

- P.001** **REGULATOR COMBINATIONS IDENTIFY SYSTEMIC SCLEROSIS PATIENTS WITH MORE SEVERE DISEASE**  
Y. Wang, J. Franks, D. Toledo, M. [Whitfield](#)
- P.002** **EPIGENETIC INSIGHTS FROM DIFFERENTIAL CHROMATIN ACCESSIBILITY PATTERNS IN DERMAL FIBROBLASTS AND SKIN-LIKE ORGANOID FROM PATIENTS WITH SYSTEMIC SCLEROSIS**  
T. [Wheeler](#), Y. Wang, J. Chang, D.M. Toledo, B.K. Mehta, M.S. Brown, R. Bhandari, M. Huang, T. Wood, P.A. Pioli, M.L. Whitfield
- P.003** **EXOME-WIDE ASSOCIATION ANALYSIS IDENTIFIES LRP2BP AS A SUSCEPTIBILITY GENE FOR ENDOTHELIAL INJURY IN SYSTEMIC SCLEROSIS**  
J. [Wang](#), W. Pu, W. Wu, Q. Liu, Y. Ma, W. Tu, X. Zuo, G. Guo, S. Jiang, Y. Zhao, J. Reveille, M. Mayes, J. Li, E. Lee, X. Zhang, J. Xu, Z. Zhang, X. Zhou, H. Zou
- P.004** **INCREASED PLATELET DEPOSITION UNDER SHEAR STRESS CONDITIONS IN PATIENTS WITH SCLERODERMA**  
I. [Vigdorchick](#), Y. Levy
- P.005** **ANTICENTROMERE ANTIBODY LEVELS AND ISOTYPES ASSOCIATE WITH DISEASE SEVERITY IN SYSTEMIC SCLEROSIS**  
N. [Van Leeuwen](#), J. Bakker, O. Distler, A. Hoffman-Vold, A. Grummels, C. Wortel, H. Fretheim, S. Jordan, T. Huizinga, R. Toes, H. Scherer, J. De Vries-Bouwstra
- P.006** **SPECIFIC IMMUNODOMINANT PDGF $\alpha$  AND NADPH OXIDASE HLA-I TRANS-SPICED PEPTIDES ARE DEMONSTRATED IN SSC LYMPHOCYTES**  
S. Svegliati, G. Moroncini, T. Spadoni, M. Mozzicafreddo, M. Cuccioloni, A. Grieco, C. Paolini, C. Tonnini, S. Agarbati, A. Funaro, [A. Gabrielli](#), E. Avvedimento
- P.007** **PATHOGENIC ACTIVATION OF MESENCHYMAL STEM CELLS IS INDUCED BY THE DISEASE MICROENVIRONMENT IN SYSTEMIC SCLEROSIS**  
Y. [Suleman](#), H. Liu, Z. Taki, E. Gostjeva, W. Thilly, H. Lopez, S. Vigneswaran, B. Ahmed Abdi, C. Denton, S. O Reilly, S. Xu, R. Stratton
- P.008** **ALPHA- SMOOTH MUSCLE ACTIN EXPRESSION ON ENDOTHELIAL PROGENITORS CELLS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS: POSSIBLE ROLE IN THE ENDOTHELIAL-TO-MESENCHYMAL TRANSITION PROCESS**  
K. [Stefanantoni](#), C. Barbati, T. Colasanti, C. Angelelli, G. Pellegrino, C. Alessandri, G. Valesini, V. Riccieri
- P.009** **CLINICAL SIGNIFICANCE OF ISOLATED RO52/TRIM21 AUTOANTIBODIES IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT**  
K. [Solanki](#), P. Bardoul, A. Soepnoel, D. White, M. Matucci-Cerinic
- P.010** **IS ANTI-DOUBLE-STRANDED, SINGLE-STRANDED DNA ANTI-C1Q ANTIBODY SEROPOSITIVITY A DISEASE MARKER IN PATIENTS WITH SYSTEMIC SCLEROSIS?**  
T. [Simopoulou](#), E. Patrikiou, C. Liaskos, G. Efthymiou, L. Sakkas, D. Bogdanos
- P.011** **CD34 AND ALPHA-SMOOTH MUSCLE ACTIN DISTINGUISH SCLERODERMA GENE EXPRESSION SUBSETS USING A MACHINE LEARNING APPROACH**  
K. [Showalter](#), D. Orange, C. Magro, P. Agius, V. Martyanov, J. Franks, R. Sharma, H. Geiger, T. Wood, Y. Zhang, R. Spiera, M. Whitfield, J. Gordon
- P.012** **OCCURRENCE OF DIFFERENT ANTINUCLEAR ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS POSITIVE FOR ANTI-U1RNP**  
R. [Shaykhetova](#), L. Ananieva, O. Koneva, M. Starovoitova, O. Desinova, O. Ovsyannikova, L. Garzanova
- P.013** **NOTCH SIGNALING IN MICROVASCULAR ENDOTHELIAL CELLS IS MODULATED BY A SERUM FACTOR IN SYSTEMIC SCLEROSIS**  
F. [Seguro Paula](#), J. Delgado Alves
- P.014** **SPECIFIC AUTOANTIBODIES IN SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH CLINICAL MANIFESTATION IN WEST JAVA INDONESIA**  
W. [Saragih](#), S. Dewi, R. Wachjudi, V. Logito, A. Tjandrawati
- P.015** **DISSECTING THE ROLE OF IL-25 IN KERATINOCYTE-FIBROBLAST CROSSTALK IN SYSTEMIC SCLEROSIS**  
B. [Russo](#), J. Borowczyk-Michalowska, P. Cacialli, N. Brembilla, C. Chizzolini
- P.016** **CD25+ FOXP3+ REGULATORY B CELLS FUNCTION IN SYSTEMIC SCLEROSIS**  
D. [Rimar](#), G. Slobodin, I. Rosner, M. Rozenbaum, E. Nasrin, Z. Vadasz
- P.017** **IS IGG4 AN IMMUNO-PROTECTIVE ANTIBODY? LESSONS FROM SYSTEMIC SCLEROSIS**  
N. [Rabinowicz](#), A. Ben Ari, H. Paran, Y. Levy
- P.018** **EVALUATION OF MEMBRANE-BOUND AND SOLUBLE FORMS OF HUMAN LEUCOCYTE ANTIGEN G (HLA-G) IN SYSTEMIC SCLEROSIS**  
P. Contini, S. Negrini, G. Murdaca, M. Greco, F. [Puppo](#)
- P.019** **ANTI-IFI-16 AUTOANTIBODIES IN SYSTEMIC SCLEROSIS PATIENTS ARE ASSOCIATED WITH A POORER PROGNOSIS IN OVERALL SURVIVAL**  
J. [Perurena-Prieto](#), E.L. Callejas-Moraga, A. Guillén-Del-Castillo, L. Viñas-Gimenez, A. Marin-Sánchez, V. Fonollosa-Plá, M.T. Sanz-Martinez, C. P. Simeón-Aznar
- P.020** **INKT CELLS MODULATE REGULATORY AND EFFECTOR B CELLS OF SSC PATIENTS**  
E. Asteriti, H. Keppeler, S. Duerr-Stoerzer, H. Schmid, K. Secker, [A. Pecher](#), J. Henes, R. Klein, C. Schneidawind, D. Schneidawind

## PATHOGENESIS (AUTOANTIBODIES)

- P.021** **DEFECTIVE DNA DAMAGE RESPONSE AND REPAIR NETWORK IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Pappa, P. Ntoulos, N. Vlachogiannis, S. Panopoulos, V. Bournia, V. Souliotis, P. Sfrikakis
- P.022** **SKIN SINGLE-CELL RNA SEQUENCING AND TARGET VALIDATION IN SYSTEMIC SCLEROSIS AND SCLEROTIC GVHD**  
I. Odell, R. Flavell
- P.023** **CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS NEGATIVE FOR SSC-RELATED AUTOANTIBODIES**  
M. Miyake, Y. Hamaguchi, T. Matsushita, K. Takehara
- P.024** **ROLE OF EFFECTOR AND REGULATORY B CELLS IN PATIENTS WITH SYSTEMIC SCLEROSIS: IL-6 PRODUCING EFFECTOR B CELLS ASSOCIATED WITH SKIN FIBROSIS**  
T. Matsushita, T. Kobayashi, M. Kano, Y. Hamaguchi, M. Hasegawa, M. Fujimoto, K. Takehara
- P.025** **CORRELATIONS BETWEEN NEUTROPHILS/LYMPHOCYTES RATIO AND PLATELETS/LYMPHOCYTES RATIO IN CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
F. Masini, F. Guarino, K. Gjeloshi, F. Danzo, E. Pinotti, R. Ferrara, M. Tardugno, L. Maresca, C. Romano, G. Cuomo
- P.026** **THE INTERCONNECTIONS BETWEEN ACTIVITIES OF THE OXIDATIVE-RELATED ENZYMES AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS**  
E. Mozgovaya, S. Bedina, A. Trofimenko, I. Zborovskaya, M. Mamus, E. Tikhomirova, S. Spitsina
- P.027** **THE ROLES OF PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) INHIBITOR IN SKIN FIBROBLASTS AND IN MICE MODEL OF SYSTEMIC SCLEROSIS**  
K. Makino, M. Trojanowska, H. Ihn
- P.028** **CORRELATION OF ANTINUCLEAR AUTOANTIBODIES, SOLUBLE TGF- $\beta$  ISOFORMS, AND TGFB1 +869T-C AND +915G-C POLYMORPHISMS IN PATIENTS OF SOUTHERN MEXICO WITH SYSTEMIC SCLEROSIS**  
J. Lomeli Nieto, J. Muñoz Valle, C. Baños Hernández, J. Navarro Zarza, S. García Arellano, B. Anaya Macías, C. Fuentes Baez, I. Parra Rojas, J. Hernández Bello
- P.029** **THE LABORATORY STRATEGY FOR ANTIBODIES SCREENING AND SPECIFIC ANTIGEN DETECTION AS DIAGNOSTIC MARKER OF PULMONARY FIBROSIS IN SYSTEMIC SCLEROSIS: PRELIMINARY STUDY**  
V. Logito, W. Agnestia Maranna Saragih, A. Tjandrawati, S. Dewi
- P.030** **CRYSTALLINE SILICA IMPAIRS EFFEROCYTOSIS ABILITIES OF HUMAN AND MOUSE MACROPHAGES**  
A. Lescoat, A. Ballerie, M. Lelong, Y. Augagneur, C. Morzadec, S. Jouneau, P. Jegou, O. Fardel, L. Vernhet, V. Lecureur
- P.031** **AN ITALIAN MULTICENTER STUDY ON THE ASSOCIATION OF ANTI-RNA POLYMERASE III ANTIBODY WITH BREAST CANCER AND SILICONE BREAST IMPLANTS RUPTURE IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Lazzaroni, C. Caimmi, E. Bertoldo, C. Campochiaro, G. De Luca, F. Franceschini, A. Tincani, P. Airò
- P.032** **ANTI-PM/SCL ANTIBODY IN PATIENTS WITH SYSTEMIC SCLEROSIS. ANALYSIS OF THE MULTICENTER EUSTAR COHORT, WITH A CASE-CONTROL STUDY ON ASSOCIATION WITH MALIGNANCIES**  
M. Lazzaroni, E. Marasco, C. Campochiaro, J. Devries-Bouwstra, E. Hachulla, E. Zanatta, S. Barsotti, G. Abignano, M. Truchetet, G. De Luca, E. De Langhe, R. Hesselstrand, F. Ingegnoli, E. Bertoldo, C. Caimmi, V. Smith, S. Bellando-Randone, H. Poormoghim, E. Colombo, A. Ceribelli, A. Furloni, S. Zingarelli, F. Franceschini, F. Del Galdo, C. Denton, L. Cavagna, Y. Allanore, P. Airò
- P.033** **DISCOVERY OF T CELL EPITOPES FROM THE AUTOANTIGENS IMPLICATED IN SYSTEMIC SCLEROSIS: AN IN SILICO APPROACH**  
M. Larche, B. Duvvuri, R. Quinn, M. Larche
- P.034** **THE ROLE OF DIFFERENT ANTINUCLEAR ANTIBODIES IN VASCULAR LESIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
N. Klyaus, M. Simakova, A. Maslyanskiy, O. Moiseeva
- P.035** **MALE MICROCHIMERISM IN SSC PATIENTS**  
J. Milas Ahic, Z. Kardum, S. Tokic, V. Prus
- P.036** **EPIDEMIOLOGY AND TREATMENT OF PERIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS**  
B. Almejadi, F. To, K. Devakandan, M. Anderson, S. Johnson
- P.037** **AUTOANTIBODIES TARGETING CXCR3, CXCR4 AND AT1R AFFECT THE EXPRESSION OF THEIR COGNATE RECEPTORS IN THE APOE KO MOUSE MODEL**  
L. Johanson, L. Brachaczek, Z. Aherrahrou, G. Marschner, S. Pitann, A. Kerstein-Stähle, A. Müller, H. Heidecke, C. Herden, G. Riemekasten
- P.038** **A PILOT STUDY ASSESSING THE EFFECT OF AIR POLLUTION ON EXTRACELLULAR VESICLES IN SYSTEMIC SCLEROSIS**  
F. Ingegnoli, T. Schioppa, M. Hoxha, S. Iodice, L. Pergoli, A. Murgo, L. Ferrari, V. Bollati, R. Caporali
- P.039** **SYSTEMIC SCLEROSIS WITHOUT ANTINUCLEAR ANTIBODIES: A MULTI-CENTER STUDY OF EUSTAR COHORT IN CHINA**  
M. Hui, J. Zhou, X. Duan, L. Zhang, M. Li, Q. Wang, J. Zhao, Y. Hou, D. Xu, X. Zeng
- P.040** **CD21LOW B CELLS IN SYSTEMIC SCLEROSIS: A POSSIBLE MARKER OF PULMONARY ARTERIAL HYPERTENSION**  
C. Pellicano, R. Marrapodi, G. Leodori, G. Radicchio, S. Colantuono, A. Iacolare, A. Gigante, M. Visentini, E. Rosato
- P.041** **TOXIC EXPOSURE SURVEY IN A SYSTEMIC SCLEROSIS COHORT**  
M. Freire, B. Sopena, A. Gonzalez-Quintela, C. Tolosa Vilella, A. Guillén Del Castillo, B. Mari Alfonso, J. Vargas Hitos, X. Pla Salas, C. González-Echávarri, A. Chamorro, I. Peralas Fraile, A. González García, G. de la Red Bellvis, D. Bernal Bello, A. Castro Salomó, I. Jiménez Pérez de Heredia, E. Callejas Moraga, V. Fonollosa Pla, C. Simeon Aznar, On behalf of RESCLE Investigators

### PATHOGENESIS (AUTOANTIBODIES)

- P.042 IMPROVING CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS, A EUSTAR STUDY**  
M. Elhaj, M. Boubaya, E. Siegert, V. Ricciari, P. Airò, O. Distler, Y. Allanore
- P.043 SYSTEMIC SCLERODERMA: CLINICO-IMMUNOLOGICAL CORRELATION**  
K. Echchilali, K. Ouazahrou, H. Elkabli, A. Aziz Bousfiha
- P.044 LONG NON-CODING RNA HOTAIR INDUCES MYOFIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS THROUGH EZH2 DEPENDENT DE-REPRESSION OF NOTCH SIGNALLING PATHWAY ACTIVATION**  
F. Del Galdo, C. Wasson, G. Abignano, R. Ross, H. Hermes, S. Jimenez
- P.045 TGF $\beta$  PROMOTES DNA METHYLATION OF THE SOCS3 PROMOTER TO INDUCE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC**  
C. Dees, S. Pötter, Y. Zhang, C. Bergmann, M. Luber, T. Wohlfahrt, A. Ramming, O. Distler, G. Schett, J. Distler
- P.046 IL-1 BETA-STIMULATED MICROVASCULAR ENDOTHELIAL CELLS PROMOTE M2-LIKE MACROPHAGES: CONSEQUENCES ON FIBROBLASTS ACTIVATION DURING SCLERODERMA**  
C. Contin-Bordes, P. Laurent, J. Lapoirie, B. Jurado-Mestre, E. Levionnois, M. Truchetet
- P.047 EXOSOMES IN SYSTEMIC SCLEROSIS (SSC): HOW TO SPREAD THE PRO-FIBROTIC SIGNALLING IN THE DISEASE**  
C. Corallo, M. Cutolo, S. Soldano, N. Giordano
- P.048 SERUM MARKER ANALYSIS SUGGESTS SUBSET AND STAGE SPECIFIC PROFILES OF FIBROGENESIS ACROSS THE SCLERODERMA SPECTRUM**  
K.E.N. Clark, C. Campochiaro, K. Nevin, E. Csomor, N. Galwey, M. Morse, N. Wisniacki, S. Flint, V.H. Ong, E. Derrett-Smith, C.P. Denton
- P.049 ANTIBODIES VERSUS SKIN FIBROSIS EXTENSION IN SYSTEMIC SCLEROSIS: A CASE-CONTROL STUDY**  
A. Tieu, B. Chaigne, B. Dunogue, J. Dion, A. Regent, P. Legendre, C. Le Jeune, L. Mouthon
- P.050 CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND CANCER: RESULTS OF THE SPANISH REGISTRY OF SCLERODERMA (RESCLE)**  
C. Carbonell, A. Chamorro, P. Segovia Alonso, C. Tolosa Vilella, L. Trapiella Martínez, D. Colunga Argüelles, L. Sáez Comet, M. Rubio Rivas, A. Argibay, A. Madroñero Vuelta, M. Sánchez García, M. Ruiz Muñoz, F. García Hernández, G. Espinosa, J. Ríos Blanco, E. Callejas Moraga, A. Guillén Del Castillo, V. Fonollosa Pla, C. Simeón Aznar, On behalf of Rescle Investigators
- P.051 CO-EXISTENCE OF SSC HALLMARK AUTOANTIBODIES ASSOCIATES WITH DISTINCT CLINICAL PHENOTYPE**  
C. Campochiaro, K. Clark, L. Host, S. Alper, S. Nihtyanova, C. Denton, V. Ong
- P.052 EVALUATION OF TWO DISTINCT ASSAYS FOR DETECTION OF ANTI-TH/ TO ANTIBODIES IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY**  
E. Callejas-Moraga, J. Perurena-Prieto, A. Guillén-Del-Castillo, L. Viñas-Gimenez, A. Marin-Sánchez, E. Balada-Prades, V. Fonollosa-Plá, M. Sanz-Martinez, M. Mahler, C. Simeón-Aznar

- P.053 COEXISTENCE OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS: FREQUENCY AND ASSOCIATION WITH CLINICAL CHARACTERISTICS**  
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves
- P.054 THE AP1-TRANSCRIPTION FACTOR CJUN AND THE HEDGEHOG MEDIATOR GLI2 COOPERATE TO AMPLIFY FIBROBLAST ACTIVATION AND TISSUE FIBROSIS**  
C. Bergmann, B. Merlevede, L. Hallenberger, C. Dees, C. Chen, T. Trinh-Minh, A. Bozec, G. Schett, J. Distler
- P.055 CLINICAL PREVALENCE OF ANTI-BICD2 ANTIBODIES USING A NOVEL MULTI-ANALYTE ASSAY FOR THE DIAGNOSIS OF SYSTEMIC SCLEROSIS IN A SPANISH COHORT**  
E. Ruiz-Ortiz, S. Prieto, F. Hernández-González, A. Pérez-Isidro, M. Mahler, S. Casas, C. Bentow, A. Seaman, K. Norvell, M. Tiongson, M. Aure, G. Kim, R. Cervera, O. Viñas, G. Espinosa
- P.056 THE HMGB1/AGE-RAGE AXIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: A POTENTIAL ROLE IN ITS VASCULOPATHY?**  
I.M. Atzeni, A. Eman Abdulle, A. van Roon, A.J. Smit, G.F. H. Hiercks, H. van Goor, J. Westra, D.J. Mulder
- P.057 ABERRANT EXPRESSION LEVELS OF SOLUBLE CO-INHIBITORY RECEPTORS AS MARKERS OF T CELL EXHAUSTION AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS**  
M. Aspari, V. Ong, B. Deleuran, D. Abraham
- P.058 FEATURES OF THE DEBUT OF SYSTEMIC SCLERODERMA ARE ABLE TO DETERMINE THE DISEASE PATTERN**  
A. Aleksandrov, L. Shilova, V. Aleksandrov
- P.059 A NOVEL HUMANIZED MOUSE MODEL OF SKIN FIBROSIS**  
G. Moroncini, C. Paolini, F. Orlando, A. Grieco, S. Agarbat, C. Tonnini, S. Sveglia Baroni, T. Spadoni, A. Funaro, E. Awedimento, M. Provinciali, A. Gabrielli
- P.060 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS**  
J.E. Oller Rodríguez, M. De La Rubia Navarro, E. Grau García, I. Martínez Cordellat, F.M. Ortiz Sanjuán, E. Vicens Bernabéu, R. Negueroles Albuixech, I. Chalmeta Verdejo, C. Alcañiz Escandell, C. Perales Pávez, C. González Mazarío, J.J. Frago Gil, I. Cánovas Olmos, C. Nájera Herranz, L. González Puig, J. Ivorra Cortés, J.A. Román Ivorra

### PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.061 SYSTEMIC SCLEROSIS AUTO-ANTIBODY PROFILES PREDICT INTERSTITIAL LUNG DISEASE ONSET BUT NOT PROGRESSION**  
B. Zheng, M. Wang, M.J. Fritzler, M.Y. Choi, M. Baron, M. Hudson, On Behalf of the CSRG
- P.062 TREATMENT WITH MYCOPHENOLATE MOFETIL AND CYCLOPHOSPHAMIDE LEADS TO CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE**  
E. Volkmann, D. Tashkin, H. Leclair, M. Roth, P. Clements, G. Kim, J. Goldin, D. Furst, D. Khanna

## PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.063 THE MUC5B PROMOTER VARIANT DOES NOT PREDICT RESPONSE TO IMMUNOSUPPRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE**  
E. Volkman, D. Tashkin, N. Li, J. Charles, M. Mayes, M. Roth, G. Kim, J. Goldin, P. Clements, D. Furst, D. Khanna, L. Pourzand, R. Elashoff, S. Assassi
- P.064 FATAL CONSEQUENCES OF THERAPEUTIC THORACENTESIS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
L. Vigdorchick, A. Natour, O. Wand, Y. Levy
- P.065 QUANTITATIVE CHEST COMPUTED TOMOGRAPHY (QCT) ANALYSIS OF SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH RITUXIMAB: PRELIMINARY FINDINGS**  
E. Cacciapaglia, S. Parisi, F. Montini, V. Fiore, L. Urso, E. Fusaro, A. Ariani, F. Iannone
- P.066 LUNG FIBROSIS DOES NOT IMPACT PLATELET COUNT IN SCLERODERMA PATIENTS WITH LUNG INVOLVEMENT**  
Y. Suliman, S. Kafaja, M. Alemam, D. E Furst
- P.067 SYSTEMIC LEVELS OF S100A4 CORRELATE WITH DISEASE ACTIVITY, SKIN FIBROSIS AND INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
H. Storkanova, L. Andres Cerezo, S. Oreska, M. Spiritovic, B. Hermankova, M. Komarc, K. Pavelka, J. Vencovsky, J. Distler, R. Becvar, L. Senolt, M. Tomcik
- P.068 EXTRACELLULAR HSP90 AS A POTENTIAL BIOMARKER OF SKIN AND LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
H. Storkanova, S. Oreska, M. Spiritovic, B. Hermankova, K. Bubova, M. Komarc, K. Pavelka, J. Vencovsky, J. Distler, L. Senolt, R. Becvar, M. Tomcik
- P.069 PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS – AN AUDIT OF SCREENING PRACTICES AND COST OVER 10 YEARS**  
L. Spray, J. Vila, B. Griffiths
- P.070 MANAGEMENT AND BURDEN OF DISEASE OF SSC-ILD IN EIGHT EUROPEAN COUNTRIES: RESULTS OF THE BUILDUP PROJECT**  
W. Wuyts, J. Rømhild Davidsen, M. Kilpeläinen, M. Durheim, S. Papiiris, E. Manali, J. Miedema, C. Robalo Cordeiro, A. Morais, M. Perez, G. Asjeee, S. Soulard
- P.071 NINTEDANIB INHIBITS GROWTH FACTOR INDUCED FIBROSIS IN AN IN VITRO FIBROBLAST MODEL OF SYSTEMIC SCLEROSIS**  
A. Siebühr, M. Karsdal, A. Bay-Jensen, P. Juhl
- P.072 PLEURO-PARENCHYMAL FIBROELASTOSIS IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE**  
A. Sari, O. Onder, B. Armagan, E. Bolek, B. Farisogullari, E. Bilgin, G. Yardimci, M. Ariyurek, A. Akdogan
- P.073 COMPARISON BETWEEN DIFFERENT THERAPEUTICAL APPROACH TO SYSTEMIC SCLEROSIS (SSC) RELATED INTERSTITIAL LUNG DISEASE (ILD)**  
M. Saracco, T. Oddenino, C. Lomater
- P.074 WHICH TREATMENT ASPECTS MATTER TO PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE? THE DEVELOPMENT OF A PATIENT PREFERENCE INSTRUMENT**  
L. Saketkoo, C. Bruni, N. Schoof, S. Heidenreich, A. Duenas, M. Alves, A. Hoffmann-Vold, A. Gabrielli, O. Distler
- P.075 PREVALENCE AND SURVIVAL OF SYSTEMIC SCLEROSIS (SSC) AND ASSOCIATED INTERSTITIAL LUNG DISEASE IN ONTARIO, CANADA OVER 10 YEARS**  
J. Pope, K. Quansah, M. Kolb, J. Flavin, S. Hassan, S. Seung, K. Garlick
- P.076 CORRELATION BETWEEN PARAMETERS OF PULMONARY FUNCTION AND ANTI-SCL-70 ANTIBODIES IN THE PATIENTS WITH SSC AND ILD OVER 5 YEAR FOLLOW UP**  
O. Ovsyannikova, O. Koneva, L. Ananieva, L. Garzanova, O. Desinova, M. Starovoytova
- P.077 ASSOCIATION PROGRESSION PULMONARY ALTERATIONS BY HRCT OF WITH EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX (ECSG-AI) IN PATIENTS WITH SYSTEMIC SCLEROSIS OVER A FIVE YEAR PERIOD**  
O. Ovsyannikova, O. Koneva, L. Ananieva, L. Garzanova, O. Desinova, M. Starovoytova
- P.078 PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASSIFICATION?**  
F. Ortiz-Sanjuán, C. Alcañiz, I. Cánovas, I. Chalmeta, M. De La Rubia, J. Frago, R. González, L. González, E. Grau, S. Leal, I. Martínez, C. Nájera, R. Negueroles, C. Pavez, J. Oller, E. Vicens, J. Ivorra, J. Román-Ivorra
- P.079 FORCED VITAL CAPACITY TRAJECTORIES IN PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY FIBROSIS**  
S.I. Nihtyanova, E.C. Derrett-Smith, C. Fonseca, V.H. Ong, C.P. Denton
- P.080 ABNORMAL ESOPHAGOGRAM PREDICTS PULMONARY FUNCTION DETERIORATION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
L. Gigante, E. De Lorenzis, G. Natalello, L. Berardini, Giovanni B. Canestrari, L. Verardi, E. Gremese, L. Richeldi, S. Bosello
- P.081 ESOPHAGEAL EROSIONS PREDICT PROGRESSION OF LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
E. De Lorenzis, G. Natalello, L. Berardini, Giovanni B. Canestrari, L. Gigante, L. Verardi, E. Gremese, L. Richeldi, S. Bosello
- P.082 OUTCOME OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SCLERODERMA: A 5 YEAR PROSPECTIVE COHORT STUDY**  
R. Nanavati, R. Samant, A. Khune
- P.083 ANALYSIS OF SERUM CARBOHYDRATE ANTIGENS (CA 19-9, CA 125, CA 15-3), CARCINOEMBRYONIC ANTIGEN AND ALPHA FETOPROTEIN IN SYSTEMIC SCLEROSIS PATIENTS WITH ASSOCIATED INTERSTITIAL LUNG DISEASES (ILD)**  
C. Naclerio, A. Cavallera, T. Urraro, S. Scarpatò
- P.084 A NEW FUNCTIONAL STAGING OF SSC-RELATED INTERSTITIAL LUNG DISEASE WITH PROGNOSTIC IMPLICATIONS**  
A. Santaniello, L. Bettolini, C. Bellocchi, M. Cassavia, G. Montanelli, B. Vigone, A. Severino, M. Caronni, C. Campochiaro, E. De Lorenzis, L. Cavagna, G. De Luca, S. Bosello, L. Beretta

## PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.085** **PREVALENCE AND CLINICAL PRESENTATION OF SSC-ASSOCIATED ILD ACCORDING TO WORLDWIDE SPATIAL REPARTITION IN THE EUSTAR DATABASE**  
A. Lescoat, D. Huscher, E. Hachulla, C. Denton, M. Matucci-Cerinic, G. Riemekasten, F. Del Galdo, C. Caimmi, M. Truchetet, N. Schoof, O. Distler, Y. Allanore
- P.086** **EVALUATION OF THE RITUXIMAB LOW DOSES EFFECT ON SYSTEMIC SCLEROSIS CLINICAL MANIFESTATIONS AND ACTIVITY**  
O. Koneva, L. Ananyeva, L. Garzanova, O. Desinova, O. Ovsyannikova, M. Starovoytova
- P.087** **EVALUATION OF THE RITUXIMAB MONOTHERAPY EFFICACY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE**  
O. Koneva, L. Ananyeva, L. Garzanova, O. Desonova, O. Ovsyannikova, M. Starovoytova
- P.088** **USE OF IMMUNOSUPPRESSANTS AND CLINICAL OUTCOMES AMONG PATIENTS WITH SYSTEMIC SCLEROSIS AND SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A US COHORT STUDY**  
 Q. Li, L. Wallace, P. Patnaik, M. Alves, M. Gahlemann, Y. Kohlbrenner, C. Raabe, J.R. Wang, L.M. Garry
- P.089** **DISEASE FREQUENCY AND CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A US COHORT STUDY**  
 Q. Li, L. Wallace, P. Patnaik, M. Alves, M. Gahlemann, Y. Kohlbrenner, C. Raabe, Jocelyn R. Wang, E.M. Garry
- P.090** **EFFECT OF NINTEDANIB ON PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): FURTHER ANALYSES OF THE SENSISC TRIAL**  
D. Khanna, D. Furst, M. Aringer, M. Cutolo, I. Castellvi, T. Luckhardt, C. Stock, M. Alves, M. Gahlemann, O. Distler
- P.091** **EVIDENCE-BASED CONSENSUS STATEMENTS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**  
A. Hoffmann-Vold, T. Maher, A. Ashrafzadeh, O. Distler
- P.092** **PREVENTION OF INTERSTITIAL LUNG DISEASE WITH IMMUNOSUPPRESSIVE THERAPY IN SYSTEMIC SCLEROSIS**  
S. Hoa, S. Bernatsky, S. Proudman, W. Stevens, J. Sahhar, M. Wang, Russell J. Steele, M. Baron, M. Nikpour, M. Hudson
- P.093** **ANALYSIS OF SYSTEMIC SCLEROSIS LUNG DISEASE WITH CELLPHONEDB**  
M. Hinchcliff, I. Odell
- P.094** **A THIRTEEN-YEAR SINGLE-CENTER EXPERIENCE IN SYSTEMIC SCLEROSIS AND LUNG TRANSPLANTATION**  
P. Gubern Prieto, A. Guillén-Del-Castillo, C. Berastegui García, A. Román-Broto, C. Bravo-Masgoret, M. López-Meseguer, I. Bello-Rodríguez, E. Callejas-Moraga, I. Sanz-Pérez, M. Roca-Herrera, V. Fonollosa-Pla, C. Simeón-Aznar
- P.095** **THE ROLE OF NAILFOLD CAPILLAROSCOPY IN MONITORING LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
L. Groseanu, P. Paraschiva, A. Balanescu, V. Bojinca, D. Opris-Belinski, A. Borangiu, I. Saulescu, D. Mazilu, S. Daia-Iliescu, F. Berghea, C. Constantinescu, M. Negru, M. Abobului, C. Cobilinschi, R. Ionescu
- P.096** **CALIPER: EVALUATION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**  
 G. Leodori, C. Pellicano, A. Villa, A. Iacolare, A. Gigante, A. Ferrazza, M. Gasperini, I. Carbone, E. Rosato
- P.097** **SELF-REPORTED SYSTEMIC SCLEROSIS-RELATED AND PULMONARY SYMPTOMS ARE MORE PREVALENT IN SUBJECTS WITH RAYNAUD'S IN THE GENERAL POPULATION**  
 A. Eman Abdulle, K. de Leeuw, L. Brouwer, S. Arends, C. Tji Gan, A. Herrick, H. van Goor, U. Mulder
- P.098** **CIRCULATING BIOMARKERS IN INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A META-ANALYSIS**  
M. Elhai, J. Avouac, Y. Allanore
- P.099** **SYSTEMIC MICROANGIOPATHY IN PULMONARY ARTERIAL HYPERTENSION: PRELIMINARY DATA FROM A CROSS-SECTIONAL STUDY**  
T. Dimitroulas, A. Arvanitaki, G. Giannakoulas, E. Triantafyllidou, C. Feloukidis, P. Rouskas, S. Mouratoglou, H. Karvounis, A. Garyfalos
- P.100** **CORRELATION BETWEEN HRCT SCORE WITH PULMONARY FUNCTION TEST ON SYSTEMIC SCLEROSIS PATIENTS**  
A. Sudianto, H. Soekersi, I. Hasan Hikmat, S. Dewi, H. Yani &, I. Desrianda
- P.101** **HAEMOSTATIC FUNCTION AND FIBRIN CLOT PROPERTIES IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
J. Colic, A. Antovic, I. Pruner, J. Vojinovic, M. Sefik-Bukilica, N. Damjanov
- P.102** **EVOLUTION OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE ONE YEAR AFTER TREATMENT WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CYCLOPHOSPHAMIDE**  
J. Ciaffai, N.M. Van Leeuwen, M. Boonstra, L.J.M. Kroft, A.A. Schouffoer, M.K. Ninaber, T.W.J. Huizinga, J.K. De Vries-Bouwstra
- P.103** **EFFECTS OF NINTEDANIB IN PATIENTS WITH EXTENSIVE AND LIMITED SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD): FURTHER ANALYSES OF THE SENSISC TRIAL**  
D. Christopher, N. Goh, D. Lynch, T. Maher, V. Smith, V. Cottin, R. Spiera, C. Stock, M. Gahlemann, M. Alves, A. Wells
- P.104** **FOLLOW-UP EVALUATION OF A PROTOCOL-BASED TREATMENT FOR SYSTEMIC SCLEROSIS RELATED-INTERSTITIAL LUNG DISEASE**  
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves
- P.105** **THE LINK BETWEEN PARENCHYMAL AND VASCULAR FEATURES IN SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD): A QUANTITATIVE ANALYSIS OF IMAGING FEATURES AT CHEST CT**  
C. Bruni, M. Occhipinti, G. Camiciottoli, M. Bartolucci, M. Pienn, G. Lepri, A. Fabbrizzi, A. Tottoli, G. Ciardi, D. Giuggioli, G. Cuomo, F. Masini, H. Olschewski, F. Lavorini, S. Colagrande, M. Matucci Cerinic

## PULMONARY INCLUDING INTERSTITIAL LUNG DISEASE AND PULMONARY

- P.106** **SCREENING TOOLS FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC): A SYSTEMATIC LITERATURE REVIEW (SLR)**  
C. Bruni, G. De Luca, M. Lazzaroni, E. Zanatta, M. Matucci Cerinic
- P.107** **CARDIAC CATHETERIZATION VERSUS ECHOCARDIOGRAPHY FOR MONITORING PULMONARY PRESSURE: A PROSPECTIVE STUDY IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION**  
V. Bourmia, I. Tsangaris, L. Rallidis, D. Konstantonis, F. Frantzeskaki, A. Anthe, S. Orfanos, E. Demerouti, P. Kariofyllis, V. Voudris, A. Laskari, S. Panopoulos, P. Vlachoyiannopoulos, P. Sfikakis
- P.108** **A SINGLE HUNGARIAN PULMONOLOGY CENTER EXPERIENCE ON SCLERODERMA RELATED INTERSTITIAL LUNG DISEASES**  
A. Bohács, K. Vincze, E. Kiss, A. Polgár, Á. Tárnoki, D. Tárnoki, K. Karlócai, K. Karlinger, V. Müller
- P.109** **TREATMENT WITH A THROMBIN INHIBITOR, DABIGATRAN ETEXILATE, REDUCES PROTOTYPIC MARKER OF DIFFERENTIATED MYOFIBROBLASTS IN SCLERODERMA LUNG**  
G. Bogatkevich, I. Atanelishvili, R. Silver
- P.110** **EFFECT OF NINTEDANIB ON PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) OVER 100 WEEKS: DATA FROM THE SENSISC TRIAL**  
S. Assassi, O. Distler, Y. Allanore, T. Ogura, J. Varga, S. Vettori, B. Crestani, U. Von Wangenheim, M. Quaresma, M. Alves, S. Stowasser, T. Maher
- P.111** **DLCO IN MONITORING AND MANAGING DISEASE PROGRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE**  
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, T. Cernomaz, R. Chiriac
- P.112** **PROFIBROTIC PROTEINS DOWNSTREAM OF THROMBIN RECEPTOR PAR-1 ARE DECREASED IN LUNG SCLERODERMA FIBROBLASTS FOLLOWING DABIGATRAN TREATMENT**  
G.S. Bogatkevich, I. Atanelishvili, R.M. Silver

## ARTERIAL HYPERTENSION

- P.113** **SKIN INVOLVEMENT AND PERIPHERAL VASCULAR SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ASSOCIATED PULMONARY ARTERIAL HYPERTENSION**  
N. Yudkina, A. Volkov, E. Nikolaeva, I. Kurmukov
- P.114** **SUBTYPE OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS**  
N. Yudkina, A. Volkov, E. Nikolaeva, I. Kurmukov
- P.115** **ASSOCIATION BETWEEN IRON STUDIES AND PULMONARY HAEMODYNAMICS IN SYSTEMIC SCLEROSIS**  
A. Sari, S.I. Nihtyanova, B.E. Schreiber, G. Coghlan, Christopher P. Denton, V.H. Ong

- P.116** **DELAYED RECOVERY OF ELEVATED PULMONARY ARTERIAL PRESSURE AFTER EXERCISE AS AN EARLY SIGN OF PULMONARY VASCULAR REMODELING LEADING TO PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
K. Sakurai, Y. Yamasaki, K. Suzuki, Y. Asari, T. Suzuki, T. Kiyokawa, Y. Akashi, S. Kou, H. Yamada, K. Kawahata
- P.117** **CHANGE IN PHYSICAL FUNCTION IN SYSTEMIC SCLEROSIS PATIENTS WITH INTERMEDIATE/HIGH RISK FOR PULMONARY HYPERTENSION – CLINICAL IMPLICATION OF ENDOTHELIN-RECEPTOR ANTAGONIST TREATMENT**  
J. Park, H. Choi, E. Park, H. Kwon, S. Cho, E. Lee
- P.118** **EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN DAILY CLINICAL PRACTICE, A CASE SERIES**  
J. Lemmers, H. Fretheim, H. Knaapen-Hans, F. van den Hoogen, J. van Haaren-Willems, T. Duijnhouwer, A. van Dijk, C. van den Ende, A. Hoffmann-Vold, M. Vonk
- P.119** **APPLYING THE PROPOSED DEFINITION FOR PULMONARY HYPERTENSION IN A SYSTEMIC SCLEROSIS COHORT**  
D. Langli, H. Fretheim, H. Marjavana Inseth, Ø. Midtvedt, T. Garen, Ø. Molberg, E. Gude, A. Andreassen, A. Hoffmann-Vold
- P.120** **NAILFOLD CAPILLAROSCOPY PARAMETERS AS PREDICTORS OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
N. Klyaus, M. Simakova, A. Maslyanskiy, O. Moiseeva
- P.121** **TREATMENT EFFECTS ON OUTCOME IN SYSTEMIC SCLEROSIS PATIENTS WITH MILDLY ELEVATED PULMONARY PRESSURE**  
H. Fretheim, D. Langli, H. Inseth, Ø. Midtvedt, T. Garen, Ø. Molberg, E. Gude, Arne K. Andreassen, A. Hoffmann-Vold
- P.122** **EFFICACY OF TARGETED THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
M. Erdogan, S. Esatoglu, V. Hamuryudan, G. Hatemi
- P.123** **COMPARISON OF DIFFERENT PULMONARY HYPERTENSION SCREENING ALGORITHMS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Erdogan, B. Kilickiran Avcı, Y. Ersoy, C. Ebrén, Z. Ongen, G. Ongen, V. Hamuryudan, G. Hatemi
- P.124** **SCREENING FOR THE EARLY DETECTION OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC): A META-ANALYSIS OF LONG-TERM OUTCOMES**  
Z. Brown, D. Hansen, W. Stevens, S. Proudman, M. Nikpour
- P.125** **RETROSPECTIVE EVALUATION OF THE ASIG AND DETECT ALGORITHMS FOR THE EARLY DETECTION OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC SCLEROSIS (SSC)**  
Z. Brown, D. Hansen, M. Wilson, L. McWilliams, L. Spargo, J. Walker, W. Stevens, S. Proudman, M. Nikpour

## ARTERIAL HYPERTENSION

- P.126** **RETROSPECTIVE VALIDATION OF THE ESC/ERS RISK PREDICTION MODEL IN SYSTEMIC SCLEROSIS (SSC) PATIENTS WITH NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION (PAH)**  
Z. Brown, D. Hansen, M. Wilson, J. Roddy, G. Ngian, J. Sahhar, K. Morrisroe, J. Walker, S. Proudman, W. Stevens, M. Nikpour
- P.127** **FINDINGS OF EXERCISE ULTRASOUND CARDIOGRAPHY IN PRE-PAH PATIENTS WITH SYSTEMIC SCLEROSIS ARE CORRELATED WITH EXTENT OF CAPILLARY LOSS DETECTED BY NAILFOLD VIDEOCAPILLAROSCOPY**  
K. Ashihara, T. Naganawa, M. Hoshino, Y. Kato, S. Fukaya, S. Yoshida, H. Yasuoka

## CARDIAC

- P.128** **MEAN PLATELET VOLUME AS A POTENTIAL BIOMARKER OF IMPAIRED RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
S. Jaksic Jurinjak, S. Tomasinec, M. Lucijanic, D. Delic-Brkljadic, M. Culo, J. Morovic-Vergles
- P.129** **CORONARY ARTERY CALCIFICATIONS ARE ASSOCIATE TO HEART ARRHYTHMIA BUT NOT TO CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS**  
C. Rotondo, S. Sciacca, L. Lops, A. Corrado, F. Cantatore
- P.130** **FACTORS ASSOCIATED WITH CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS. EVALUATION IN A COHORT OF 139 PATIENTS**  
A. Raschia, P. Sansinanea, M. Martire, L. Garcia
- P.131** **RIGHT HEART CATHETERISATION AND CARDIAC MAGNETIC RESONANCE IMAGING FINDINGS IN SYSTEMIC SCLEROSIS PATIENTS REFERRED FOR AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT**  
R. Penglase, A. Jabbour, E. Kotlyar, L. Gergis, D. Ma, J. Moore
- P.132** **ELECTROCARDIOGRAPHIC ABNORMALITIES AND PULMONARY INVOLVEMENT IN A MONOCENTRIC COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
G. Pellegrino, F. Facioni, K. Stefanantoni, C. Angelelli, C. Vizza, R. Badagliacca, S. Morelli, G. Valesini, V. Riccieri
- P.133** **ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES IN SYSTEMIC SCLEROSIS, A CLUE FOR PRIMARY HEART INVOLVEMENT**  
G. Natalello, G. De Luca, Giovanni B. Canestrari, E. De Lorenzis, C. Campochiaro, L. Gigante, L. Verardi, B. Toluoso, E. Gremese, L. Dagna, S. Bosello
- P.134** **THE ROLE OF CARDIOPULMONARY EXERCISE TEST (CPET) FOR DETECTING PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS PATIENTS**  
I. Litinsky, A. Man, D. Paran, S. Borok, M. Berman, U. Arad, M. Anouk, R. Zemach, O. Elkayam

- P.135** **EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF SYSTEMIC SCLEROSIS-RELATED MYOCARDITIS; A RETROSPECTIVE STUDY FROM IRANIAN SYSTEMIC SCLEROSIS REGISTRY**  
H. Kavousi, Z. Javadi Nejad, A. Javinani, A. Jamshidi, Z. Tamartash, F. Gharibdoost
- P.136** **NON-INVASIVE CARDIAC IMAGING TECHNIQUES FOR THE EVALUATION OF THE CARDIOVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
A. Guillen-Del-Castillo, C. Espinet, M. Pizzi, A. Roque, V. Pineda, I. Sanz, E. Callejas-Moraga, P. Gubern, S. Aguade, V. Fonollosa, C. Simeón-Aznar
- P.137** **MYOCARDIAL FIBROSIS IN SYSTEMIC SCLEROSIS ASSESSED BY CARDIAC MAGNETIC RESONANCE IS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION**  
G. Leodori, C. Pellicano, V. Anna Lisa, A. Iacolare, A. Gigante, N. Galea, M. Gasperini, I. Carbone, E. Rosato
- P.138** **ASSOCIATED FACTORS OF EARLY-ONSET PULMONARY HYPERTENSION AND CLINICAL DIFFERENCE BETWEEN EARLY- AND LATE-ONSET PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS**  
C. Foocharoen, T. Krikeerati, B. Pussadhamma, A. Mahakkanukrauh, S. Suwannaroj, R. Nanagara
- P.139** **CLINICAL OUTCOMES OF MYOCARDITIS AFTER STEROID THERAPY IN SYSTEMIC SCLEROSIS: A PILOT STUDY**  
C. Foocharoen, B. Pussadhamma, N. Chaosuwannakit, T. Tipparot, A. Mahakkanukrauh, S. Suwannaroj, R. Nanagara
- P.140** **SYSTEMIC SCLEROSIS IS ASSOCIATED WITH IMPAIRED CORONARY FLOW RESERVE ON 82-RUBIDIUM POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY**  
A. Feher, N. Boutagy, E. Oikonomou, S. Thorn, Y. Liu, E. Miller, A. Sinusas, M. Hinchcliff
- P.141** **DECLINE IN SUBCLINICAL SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT ASSOCIATES WITH POOR PROGNOSTIC FACTORS AND ACTIVE INTERSTITIAL LUNG DISEASE**  
R. Dumitru, L. Bissell, B. Erhayiem, G. Fent, A. Kidambi, G. Abignano, John P. Greenwood, J. Biglands, F. Del Galdo, S. Plein, M. Buch
- P.142** **PROGRESSION OF SUBCLINICAL MYOCARDIAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
D. Benfaremo, L. Manfredi, L. Zuliani, G. Stronati, F. Guerra, A. Ferrarini, C. Fischetti, M. Danielli, A. Capucci, A. Gabrielli
- P.143** **ROLE OF RIGHT VENTRICULAR STRAIN AND 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
A. Spinella, P. Macripò, E. Cocchiara, E. Galli, F. Lumetti, L. Magnani, F. Coppi, A. Mattioli, R. Rossi, G. Boriani, C. Salvarani, D. Giuggioli
- P.144** **SUCCESSFUL TAVI PROCEDURE FOR REPAIR OF AORTIC STENOSIS IN SSC PATIENTS**  
A. Balbir Gurman, A. Kerner, Y. Agmon, Y. Braun-Moscovici

## OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.145** **THE CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS WITH LUNG CANCER: DATA FROM SINGLE CENTER IN CHINA**  
H. Zhong, J. Zhou, S. Zhang, Y. Xu, Y. Hou, M. Li, D. Xu, M. Wang, X. Zeng
- P.146** **DEVELOPMENT OF A PATIENT-CENTRED ILOPROST AND ALPROSTADIL INFUSION INFORMATION SHEET FOR PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Yelovich, K. Beattie, A. Gardner, C. Whisken, N. Khalidi, M. Larche
- P.147** **THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE ANALYSIS OF 278 PATIENTS**  
Y. Yalcinkaya, N. Aliyeva, S. Amikishiyev, Y. Çagatay, B. Artım Esen, A. Gul, L. Ocal, M. Inanc
- P.148** **EVALUATION OF DIFFERENT CLASSIFICATION CRITERIA IN SYSTEMIC SCLEROSIS IN A TURKISH COHORT: THE IMPORTANCE OF NON-SKIN MANIFESTATIONS, SEROLOGY AND CAPILLAROSCOPY**  
Y. Yalcinkaya, S. Amikishiyev, N. Aliyeva, B. Artım Esen, A. Gul, L. Ocal, M. Inanc
- P.149** **DIFFERENCES BETWEEN LATE AND EARLY-ONSET SYSTEMIC SCLEROSIS**  
E. Wielosz, M. Dryglewska, M. Majdan
- P.150** **THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK – SCLERODERMA SUPPORT GROUP LEADER EDUCATION (SPIN-SSELD) PROGRAM: NON-RANDOMISED FEASIBILITY TRIAL**  
B. Thombs, L. Dyas, M. Pépin, K. Aguila, M. Carrier, L. Tao, S. Harb, V. Malcarne, G. El-Baalbaki, S. Peláez, M. Sauve, M. Hudson, R. Platt
- P.151** **PERCEIVED BARRIERS AND FACILITATORS OF USING SYNCHRONOUS TELEREHABILITATION OF PHYSICAL AND OCCUPATIONAL THERAPY IN MUSCULOSKELETAL DISORDERS: A SCOPING REVIEW**  
L. Tao, L. Kwakkenbos, A. Carboni-Jiménez, K. Turner, K. Aguila, J. Boruff, S. Ahmed, B. Thombs
- P.152** **CHARACTERISTICS OF CRP POSITIVE SYSTEMIC SCLEROSIS (SSC)**  
K. Takagi, Y. Kawaguchi, T. Higuchi
- P.153** **RELIABILITY OF WORLD SCLERODERMA FOUNDATION (WSF) DEFINITION OF SKIN ULCERS IN SCLERODERMA, RESULTS FROM THIRD CONSENSUS MEETING**  
Y. Suliman, C. Bruni, E. Praino, D. Khanna, Y. Allanore, A. L. Herrick, C. Denton, M. Matucci-Cerinic, D.E. Furst
- P.154** **ENERGY LEVEL: AN OVERLOOKED FACTOR IN ASSESSMENT OF SCLERODERMA PATIENTS**  
Y. Suliman, S. Kafaja, M. Alemam, D.E. Furst
- P.155** **HOW DO PATIENTS WITH SYSTEMIC SCLEROSIS EXPERIENCE CURRENTLY PROVIDED HEALTH CARE AND HOW SHOULD WE MEASURE ITS QUALITY?**  
J. Spierings, C. Van Den Ende, R. Schriemer, H. Bernelot Moens, E. Van Der Bijl, F. Bonte-Mineur, M. De Buck, M. De Kanter, H. Knaapen-Hans, J. Van Laar, U. Mulder, J. Potjewijd, L. De Punder, T. Schoonbrood, A. Schouffoer, A. Stel, W. Vercoutere, A. Voskuyl, J. De Vries-Bouwstra, M. Vonk
- P.156** **TREATMENT DECISION-MAKING IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A PATIENT'S PERSPECTIVE**  
J. Spierings, F. Van Rhijn-Brouwer, C. De Bresser, P. Mosterman, A. Pieterse, M. Vonk, A. Voskuyl, J. De Vries-Bouwstra, M. Kars, J. Van Laar
- P.157** **REVIEW OF MALIGNANCIES IN OUR WAIKATO COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
K. Solanki, M. Rees, C. Frampton, D. White
- P.158** **HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) AND PATIENT GLOBAL ASSESSMENT OF HEALTH (PTGA) CORRELATE WITH CHANGES IN PATIENT-REPORTED OUTCOMES (PROS)**  
R. Spiera, L. Hummers, L. Chung, T. Frech, R. Domsic, V. Hsu, D. Furst, J. Gordon, M. Mayes, R. Simms, E. Lee, S. Constantine, B. Conley, Q. Dinh, B. Bloom, B. White
- P.159** **PATIENT AND PHYSICIAN OPINIONS OF CLINICAL BENEFIT AT 3 MONTHS IN A CLINICAL TRIAL CORRELATE WITH PATIENT-REPORTED OUTCOMES (PROS)**  
R. Spiera, L. Hummers, L. Chung, T. Frech, R. Domsic, V. Hsu, D. Furst, J. Gordon, M. Mayes, R. Simms, E. Lee, S. Constantine, B. Conley, Q. Dinh, B. Bloom, B. White
- P.160** **CHANGES IN INITIAL CLINICAL PRESENTATIONS OF SYSTEMIC SCLEROSIS OVER 25 YEARS OF OBSERVATION**  
V. Semenov, I. Molokova, T. Lysunets, O. Kuryata
- P.161** **DESIGNING DUTCH RECOMMENDATIONS ON NONPHARMACOLOGIC INTERVENTIONS FOR PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Schriemer, J. Spierings, C. Van Den Ende, L. De Punder, M. Vonk, J. De Vries-Bouwstra, S. Dittmar
- P.162** **CONCURRENT AUTOIMMUNE DISORDERS AND THEIR IMPACT ON CLINICAL PRESENTATION IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS**  
C. Rotondo, A. Corrado, G. Bellantuono, F. Cantatore
- P.163** **STUDY OF THE EPIDEMIOLOGICAL, CLINICAL AND ANALYTICAL CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND CANCER IN VALL D'HEBRON HOSPITAL**  
M. Roca, A. Guillén, E. Callejas, D. Bernal, J. Hernando, P. Gubern, I. Sansano, J. Perurena, M. Sanz, J. Taberner, V. Fonollosa, C. Simeón
- P.164** **TRAJECTORIES OF PAIN IN SYSTEMIC SCLEROSIS**  
R. Robyn Wojcik, L. Kwakkenbos, M. Carrier, Donald E. Bailey, M. Krisely, Tamara J. Somers, S. Bartlett, J. Pope, W.R. Nielson, K. Nielson, B.D. Thombs, S. Silva and the SPIN Investigators
- P.165** **LOWER MORTALITY RATE BUT COMPARABLE CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS IN CRETE-GREECE AS COMPARED TO OTHER EUROPEAN COUNTRIES**  
A. Repa, S. Pitsigavdaki, A. Molla Ismail Sali, N. Kougkas, M. Terixaki, N. Avgoustidis, P. Sidiropoulos, G. Bertias
- P.166** **ASSESSMENT OF THE ACCURACY OF USING ICD-10 CODES TO IDENTIFY SYSTEMIC SCLEROSIS**  
S. De Almeida Chaves, H. Derumeaux, P. Do Minh, M. Lapeyre-Mestre, G. Moulis, G. Pugnet



## OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.167 TREATMENT MODALITIES AND DRUG SURVIVAL IN A SYSTEMIC SCLEROSIS REAL –LIFE PATIENT COHORT**  
S. Panopoulos, K. Chatzidionysiou, M. Tektonidou, A. Drosos, N. Lioussis, T. Dimitroulas, L. Sakkas, D. Boumpas, P. Voulgari, D. Daoussis, K. Thomas, G. Georgiopoulos, G. Vosvotekas, G. Bertisias, P. Sidiripoulos, D. Vassilopoulos, G. Sfrikakis
- P.168 PREVALENCE, SEVERITY AND CLINICAL CORRELATES OF SYMPTOMS OF AUTONOMIC DYSFUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
P. Ostojic, M. Atanaskovic Popovic, M. Vujovic, M. Perovic
- P.169 TOLERABILITY AND SAFETY OF ACETYSALICYLIC ACID IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
L. Verardi, E. De Lorenzis, G. Nataello, G.B. Canestrari, L. Gigante, E. Gremese, S. Bosello
- P.170 PATIENT-LEVEL EVALUATION OF COMPONENTS OF THE ACR COMBINED RESPONSE INDEX IN SYSTEMIC SCLEROSIS (CRISS) USING PATIENT-REPORTED ANCHORS**  
V. Nagaraja, J. Powers, C. Lin, V. Berrocal, D. Khanna
- P.171 A LATE ONSET OF SYSTEMIC SCLEROSIS IS ASSOCIATED WITH A MORE RAPIDLY PROGRESSING CLINICAL PHENOTYPE - DATA OF THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS**  
P. Moinzadeh, S. Hamacher, E. Siegert, U. Mueller-Ladner, G. Riemekasten, C. Guenther, I. Koetter, J. Henes, N. Blank, G. Zeidler, C. Pfeiffer, A. Juche, I. Jandova, J. Ehrchen, M. Schmalzing, L. Susok, T. Schmeiser, C. Sunderkoetter, J.H.W. Distler, N. Hunzelmann
- P.172 DECREASED ORAL APERTURE IS A POOR PROGNOSTIC FACTOR IN SYSTEMIC SCLEROSIS**  
T. Minier, V. Lóránd, Z. Bálint, D. Komjáti, B. Németh, K. Filipánits, A. Kovács, G. Nagy, C. Varjú, L. Czirák, G. Kumánovics
- P.173 THE RELATIONSHIP OF PATIENT SOCIODEMOGRAPHIC AND SCLERODERMA DISEASE CHARACTERISTICS WITH SOCIAL INTERACTION ANXIETY: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY**  
A. Meier, S. Gholizadeh, B. Ataseven, S. Roesch, M. Carrier, L. Kwakkenbos, B. Thombs, V. Malcarne, K. Gottesman
- P.174 THE IMPORTANCE OF A SYSTEMIC SCLEROSIS CLINIC IN A TERTIARY REFERRAL CENTER**  
P. Martins, E. Dourado, J. Fonseca, I. Cordeiro, C. Resende
- P.175 RELATIONSHIP BETWEEN DISEASE ACTIVITY/SEVERITY/DAMAGE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH LOCALIZED SCLERODERMA: A CROSS-SECTIONAL STUDY**  
A. Lis-Swiety, A. Skrzypek- Salamon, I. Ranosz-Janicka, L. Brzezinska-Wcislo
- P.176 DEVELOPMENT AND EVALUATION OF A PATIENT DECISION AID FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS**  
L. Kwakkenbos, M. Hudson, L. Schraven, J. Thonen-Velthuisen, B. Thombs
- P.177 REASONS FOR NOT PARTICIPATING IN SCLERODERMA PATIENT SUPPORT GROUPS: A COMPARISON OF RESULTS FROM THE NORTH AMERICAN AND EUROPEAN SCLERODERMA SUPPORT GROUP SURVEYS**  
L. Kwakkenbos, A. Carboni-Jiménez, M. Carrier, M. Pépin, S. Peláez, V. Malcarne, G. El-Baalbaki, B. Thombs
- P.178 MARKERS OF COLLAGEN TURNOVER ARE ALTERED IN PATIENTS WITH VERY EARLY SYSTEMIC SCLEROSIS: EARLY MARKERS OF TISSUE CHANGES**  
R. Dobrota, S. Jordan, P. Juhl, B. Maurer, L. Wildi, A. Bay-Jensen, M. Karsdal, A. Herrick, J. Distler, Y. Allanore, A. Hoffmann-Vold, A. Siebuhr, O. Distler
- P.179 TYPE III AND TYPE IV COLLAGEN BIOMARKERS PREDICT PROGRESSION OF FIBROSIS IN SYSTEMIC SCLEROSIS**  
R. Dobrota, S. Jordan, P. Juhl, B. Maurer, L. Wildi, A. Bay-Jensen, M. Karsdal, A. Herrick, Jörg H.W. Distler, Y. Allanore, A. Hoffmann-Vold, A. Siebuhr, O. Distler
- P.180 EPIDEMIOLOGY OF EMPLOYMENT OUTCOMES IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW**  
J. Lee, K. Devakandan, M. Anderson, M. Gignac, S. Johnson
- P.181 GASTROINTESTINAL SYMPTOM BURDEN AND QUALITY OF LIFE IN SYSTEMIC SCLEROSIS: UNDERSTANDING THE ROLE OF DIET**  
K. Jensen, L. Wang, R. Kovacic, M. Kowalczyk-Lammi, L. Saketkoo
- P.182 A SYSTEMATIC REVIEW OF INFORMATION AVAILABLE ON THE INTERNET FOR INDIVIDUALS WITH RAYNAUD'S PHENOMENON AND PATIENTS WITH SYSTEMIC SCLEROSIS**  
V. Devgire, A. Martin, R. Sandler, M. Hughes
- P.183 ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC SCLEROSIS –QUANTITATIVE ANALYSIS OF SOCIODEMOGRAPHIC, CLINICAL AND PSYCHOLOGICAL INFLUENCING FACTORS**  
S. Heyne, E. Haufe, S. Beissert, C. Günther
- P.184 DOES SCLERODERMA HAVE AN IMPACT ON SEXUAL FUNCTION AND PELVIC FLOOR FUNCTION? A CROSS-SECTIONAL STUDY IN 80 WOMEN WITH SYSTEMIC SCLEROSIS**  
B. Hermankova, S. Oreska, H. Storkanova, M. Spiritovic, K. Bubova, H. Smucrova, P. Cesak, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcic
- P.185 ERECTILE DYSFUNCTION AND SEXUAL HEALTH IN MEN WITH SYSTEMIC SCLEROSIS**  
B. Hermankova, S. Oreska, H. Storkanova, M. Spiritovic, K. Bubova, H. Smucrova, P. Cesak, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcic
- P.186 INVESTIGATING DIFFERENTIAL ITEM FUNCTIONING ON THE SOCIAL APPEARANCE ANXIETY SCALE FOR FRENCH- AND ENGLISH-SPEAKING PATIENTS: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY**  
S. Sommer, D. Harel, S. Mills, L. Kwakkenbos, M. Carrier, S. Gholizadeh, A. Portales, K. Nielson, S. Bartlett, V. Malcarne, B. Thombs
- P.187 USE OF A COHORT-BASED SURVEY TO IDENTIFY IMPORTANT BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY FOR PEOPLE WITH SCLERODERMA: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY PROTOCOL**  
S. Harb, S. Peláez, B.D. Thombs, I. Shrier, S. Patient Advisory Team

## OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.188 IDENTIFYING BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY FOR PEOPLE WITH SCLERODERMA: A NOMINAL GROUP TECHNIQUE STUDY**  
S. Harb, J. Cumin, D.B. Rice, S. Peláez, M. Hudson, S.J. Bartlett, A. Roren, D. E. Furst, Tracy M. Frech, C. Nguyen, W.R. Nielson, B.D. Thombs, I. Shrier, S. Patient Advisory Team
- P.189 A POSTER TO EXPLAIN TO THE PATIENT THE MAIN SIGNS AND SYMPTOMS OF EARLY SSC: RESULTS FROM A GP CLINIC**  
T. Pucci, L. Salvi, L. Paganelli, C. Fantauzzo, G. Gambardella, S. Bellando Randone, M. Matucci Cerinic, S. Guiducci
- P.190 THE NURSE-PATIENT RELATIONSHIP: ANIMAL ASSISTED INTERVENTION (AAI) AS A FACILITATOR**  
G. Fiori, T. Pucci, M. Zolferino, E. Corsi, A. Bartoli, D. Buttram, M. Matucci Cerinic, S. Guiducci
- P.191 DISEASE ACTIVITY INDICES IN SYSTEMIC SCLEROSIS- OLD OR NEW?**  
L. Groseanu, S. Petrescu, A. Balanescu, D. Opris-Belinski, F. Berghea, V. Bojinca, A. Borangiu, I. Saulescu, D. Mazilu, S. Daia-Iliescu, C. Constantinescu, M. Negru, M. Abobuliu, C. Coblinschi, R. Ionescu
- P.192 THE INFLUENCE OF BIOFEEDBACK COURSE ON THE QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
R. Grekhoff
- P.193 INFLUENCE OF PATIENT REPORTED "ARTHRITIS ACTIVITY" IN DETERMINING SHAQ, HAQ-DI AND COCHIN SCORES IN SYSTEMIC SCLEROSIS**  
K. Gjeloshi, F. Danzo, G. Abignano, A. Dean, F. Masini, G. Cuomo, F. Del Galdo
- P.194 A TIME SERIES ANALYSIS OF AIR QUALITY AND THE NUMBERS OF HOSPITALIZATION IN THAI SYSTEMIC SCLEROSIS PATIENTS**  
C. Foocharoen, U. Peansukwech, P. Pongkulkiat, A. Mahakkanukrauh, S. Suwannaroj
- P.195 EFFECT OF SEASON ON THE CLINICAL OUTCOMES OF THAI SYSTEMIC SCLEROSIS: AN ANALYSIS OF A NATIONWIDE THAILAND HEALTHCARE DATABASE**  
C. Foocharoen, U. Peansukwech, P. Pongkulkiat, A. Mahakkanukrauh, S. Suwannaroj
- P.196 FATIGUE IN A SERIES OF CANADIAN PATIENTS WITH SCLERODERMA**  
A. Fernandez-Codina, M. Kazem, Z. Jiang, J. Pope
- P.197 A RETROSPECTIVE ANALYSIS OF CHRONIC USE OF INTRAVENOUS PROSTACYCLIN ANALOGUES IN THE TREATMENT OF RAYNAUD'S PHENOMENON: LIMITED LONG-TERM EFFICACY**  
T. Elling, A. Abdulle, A.M. Van Roon, A.J. Stel, D.J. Mulder
- P.198 SYSTEMIC SCLEROSIS IN PATIENTS AGED LESS AND MORE THAN 60 YEARS - CLINICAL CHARACTERISTIC**  
M. Dryglewska, E. Wielosz, A. Lipska, M. Majdan
- P.199 PATHWAY TO SCLERODERMA: CONCERNING PATIENTS' EXPERIENCES DURING THE DIAGNOSTIC PROCESS**  
P. Fennell, L. Shapiro, N. Dorr, R. Lukaszewicz, F. Houser, M. Taylor
- P.200 THE DIAGNOSIS OF SCLERODERMA AS A TRAUMATIC EXPERIENCE: PATIENTS' REACTIONS TO THE DIAGNOSTIC PROCESS**  
P. Fennell, L. Shapiro, N. Dorr, R. Lukaszewicz, F. Houser, M. Taylor
- P.201 CLINICAL SIGNIFICANCE OF COGNITIVE IMPAIRMENT AND MALNUTRITION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
L. Manfredi, D. Benfaremo, G. Silvi, A. Gabrielli
- P.202 SCLERODERMA PROGRESSION AND PREGNANCY: A HOPEFUL MESSAGE FROM THE CANADIAN SCLERODERMA RESEARCH GROUP**  
S. Deshauser, M. Juneke, K. Beattie, M. Larche
- P.203 A META-ANALYSIS TO DETERMINE THE KEY FACTORS PREDICTING SKIN SCORE REGRESSION IN SYSTEMIC SCLEROSIS CLINICAL TRIALS**  
A. Degachi, J. Avouac, Y. Allanore
- P.204 CURRENT PATIENT REPORTED OUTCOMES (PROS) POORLY REFLECT CHANGES IN LUNG FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
F. Danzo, K. Gjeloshi, G. Abignano, A. Dean, F. Masini, G. Cuomo, F. Del Galdo
- P.205 LUNG FUNCTION IS ASSOCIATED WITH EQ-5D CHANGES OVER TIME IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
J. Cijffi, N.M. Van Leeuwen, M.K. Ninaber, T.W.J. Huizinga, J.K. De Vries-Bouwstra
- P.206 PREDICTORS OF PERCEIVED FUNCTIONAL STATUS IN EARLY SYSTEMIC SCLEROSIS: A PROSPECTIVE LONGITUDINAL STUDY OF THE GENISOS COHORT**  
J. Chernis, M. Buni, S. Kazkaz, J. Ying, S. Assassi, M. Mayes
- P.207 RANDOMIZED FEASIBILITY TRIAL OF THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK SELF- MANAGEMENT (SPIN-SELF) PROGRAM**  
M. Carrier, L. Kwakkenbos, W.R. Nielson, C. Fedoruk, K. Nielson, K. Millette, J. Pope, T. Frech, S. Gholizadeh, L. Hummers, S.R. Johnson, P. Piotrowski, L. Jewett, J. Gordon, L. Chung, D. Bilsker, K. Turner, J. Cumin, J. Welling, M. Sauve, T. Rodriguez Reyna, M. Hudson, M. Larche, S.J. Bartlett, V. L. Malcarne, M.D. Mayes, I. Boutron, L. Mouthon, F. Wigley, B.D. Thombs
- P.208 DISABILITY AND HIGH COSTS - TWO IMPORTANT ISSUES IN SYSTEMIC SCLEROSIS**  
A. Cardoneanu, A. Burlui, E. Rezus
- P.209 PERCEIVED BURDEN AMONG INFORMAL CAREGIVERS OF PERSONS WITH SYSTEMIC SCLEROSIS COMPARED TO OTHER CHRONIC MEDICAL CONDITIONS: A SYSTEMATIC REVIEW**  
A. Carboni-Jimenez, D.B. Rice, M. Cañedo-Ayala, B. Lewis, M. Imran, M. Chiovitti, B.D. Thombs
- P.210 NEUTROPHIL TO LYMPHOCYTE RATIO VARIATIONS IN PATIENTS DECEASED WITH SYSTEMIC SCLEROSIS**  
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.211 NEUTROPHIL TO LYMPHOCYTE RATIO AND SYSTEMIC SCLEROSIS CLINICAL IMPACT**  
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra

## OUTCOMES, QUALITY OF LIFE, PSYCHOLOGICAL & SOCIAL

- P.212 THE ROLE OF DIFFERENT SIGNS ON THE EVOLUTION OF RAYNAUD'S PHENOMENON (RP) PATIENTS TO DEFINITE SYSTEMIC SCLEROSIS (SSC): RESULTS FROM AN INTERNATIONAL MULTICENTRE STUDY ON VERY EARLY DIAGNOSIS OF SYS**  
S. [Bellando Randone](#), G. Lepri, D. Huscher, T. Minier, C. Bruni, Dan E. Furst, L. Czirkaj, M. Cutolo, V. Smith, J. Avouac, S. Guiducci, Y. Allanore, O. Distler, M. Matucci-Cerinic
- P.213 THE INFLUENCE OF SKIN CALCINOSIS ON THE PROGNOSIS OF DIGITAL ULCERS IN PATIENTS WITH SSC**  
V. [Venturini](#), S. Barsotti, M. Di Battista, A. Della Rossa, M. Mosca
- P.214 DEPRESSION IN SCLERODERMA PATIENTS, SYSTEMATIC REVIEW**  
A. [Balbir Gurrman](#), D. Israeli-Cohen, Y. Braun-Moscovici
- P.215 SERUM LEVELS OF VITAMIN D AND THE RELATIONSHIP WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
C. [Pomirleanu](#), A. Jitaru, E. Ancuta, R. Chiriac, C. Ancuta
- P.216 CAUSES OF MORTALITY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. [Aguilar Zamora](#), L. Montolio Chiva, A. Orenes Vera, I. Vazquez Gomez, E. Valls Pascual, D. Ybañez Garcia, A. Martinez-Ferrer, A. Sendra Garcia, I. Torner Hernández, V. Nuñez Monje, J. Alegre Sancho
- P.217 HAND IMPAIRMENT IN SYSTEMIC SCLEROSIS IN THE PATIENTS FROM THE REPUBLIC OF MOLDOVA**  
S. [Agachi](#), L. Groppa, E. Deseaticova, S. Popa, L. Dutca

## IMAGING

- P.218 FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A "SCLERODERMA PATTERN" FROM A "NON-SCLERODERMA PATTERN"**  
V. [Smith](#), A. Vanhaecke, A.L. Herrick, O. Distler, M.G. Guerra, C.P. Denton, E. Descheppe, I. Foeldvari, M. Gutierrez, E. Hachulla, F. Ingegnoli, S. Kubo, U. Mueller-Ladner, V. Riccieri, A. Sulli, J.M. van Laar, M.C. Vonk, U.A. Walker, M. Cutolo
- P.219 ASSESSING SKIN STIFFNESS IN SYSTEMIC SCLEROSIS THROUGH SHEAR-WAVE ELASTOGRAPHY: A FIVE-YEAR FOLLOW-UP STUDY**  
T. [Santiago](#), M. Santiago, M. Salvador, J. P. Da Silva
- P.220 EVALUATING USE OF T1-MOLLI MAPPING IN ASSESSING SYSTEMIC SCLEROSIS CARDIAC INVOLVEMENT**  
S. [Ng](#), S. Marchesseau, J. Allen, J. Totman, A. Low
- P.221 PROGNOSTIC ROLE OF CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS PATIENTS WITH PRIMARY HEART INVOLVEMENT, A FOLLOW-UP STUDY**  
G. B. Canestrari, G. De Luca, E. De Lorenzi, G. Natalello, L. Gigante, L. Verardi, F.A. Gabrielli, R. Marano, E. Gremese, S. [Bosello](#)
- P.222 USING DEEP LEARNING IN OPTOACOUSTIC AND OPTICAL NAILFOLD CAPILLAROSCOPY IMAGES TO DIFFERENTIATE BETWEEN PATIENTS WITH SSC AND CONTROLS**  
S. Nitkunanantharajah, K. Haedicke, T. Moore, J. Manning, G. Dinsdale, M. Berks, D. Jüstel, V. Ntziachristos, C. Taylor, M. Dickinson, A. Herrick, A. [Murray](#)

- P.223 WHICH NON-INVASIVE TECHNIQUES CAN BEST BE USED TO IMAGE CALCINOSIS?**  
T. Moore, E. Marjanovic, J. Manning, G. [Dinsdale](#), S. Wilkinson, M. Dickinson, A. Herrick, A. Murray
- P.224 IMAGING THE STRUCTURE AND FUNCTION OF SYSTEMIC SCLEROSIS-RELATED TELANGIECTASES; A FEASIBILITY STUDY**  
E. Marjanovic, T. [Moore](#), J. Manning, G. Dinsdale, S. Wilkinson, M. Dickinson, A. Herrick, A. Murray
- P.225 INFRARED THERMOGRAPHY FOR DIAGNOSTIC MANAGEMENT OF MICROVASCULOPATHY IN SYSTEMIC SCLEROSIS: IS IT A GOOD ALTERNATIVE FOR NAILFOLD VIDEOCAPILLAROSCOPY?**  
B. [Miziolek](#), A. Lis-Swiety, A. Skrzypek-Salamon, L. Brzezinska-Wcislo
- P.226 THYROID DISORDERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: BIOCHEMICAL AND SONOGRAPHIC CHARACTERISTICS**  
K. [Meridor](#), P. Rotman-Pikielny, M. Werner, Y. Levy
- P.227 SYSTEMIC SCLEROSIS- SPECTRUM DISEASES ELUCIDATED BY NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS AND DIGITAL OCCLUSIVE ARTERIAL DISEASE WITH LASER DOPPLER FLOWMETRY**  
A. [Makol](#), Y. Radwan, T. Gunderson, C. Crowson, A. Hinze, D. Liedl, P. Wennberg, K. Warrington
- P.228 DIAGNOSTIC PERFORMANCES OF HAND ULTRASOUND PARAMETERS AND THEIR IMPACT ON THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS**  
M. de Saint Riquier, A. Ballerie, F. Robin, N. Belhomme, C. Cazalets, C. Drotcourt, A. Perdriger, C. Yelnik, E. Hachulla, V. Sobanski, P. Jegou, G. Coiffier, A. [Lescoat](#)
- P.229 DIAGNOSING SYSTEMIC SCLEROSIS WITH PHOTOACOUSTIC AND HIGH-FREQUENCY ULTRASOUND IMAGING**  
B. Kersten, K. Daoudi, C. De Korte, F. Van Den Hoogen, E. Van Den Ende, M. [Vonk](#)
- P.230 ULTRASOUND MEASUREMENT OF THE NAIL BED MATRIX THICKNESS AS A USEFUL MARKER FOR SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE**  
V. [Hsu](#), M. Sidor, R. Zuckerman, N. Schlesinger, R. Sussman, S. Huma
- P.231 DIGITAL ARTERY VOLUME INDEX (DAVIX©) PREDICTS THE ONSET OF FUTURE DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
K. Gjeloshi, F. Danzo, G. Lettieri, G. Abignano, M. Hinton, A. Dean, G. Cuomo, O. Kubassova, F. [Del Galdo](#)
- P.232 EXAMINATION OF THE VALIDITY OF SKIN ULTRASOUND TO QUANTITATE SKIN INVOLVEMENT FOR MULTI-CENTER CLINICAL TRIALS IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)**  
O. Aly, K. [Kafaja](#), D. Furst
- P.233 NAILFOLD CAPILLAROSCOPY IN THE SPANISH GROUP OF SYSTEMIC AUTOIMMUNE DISEASES (GEAS). RESULTS OF AN ELECTRONIC SURVEY**  
P. [Fano](#), L. Saez, B. Gracia, M. Freire, Jose A. Todoli, B. Mari, G. Espinosa, F. Garcia, A. Guillén, N. Ortego, Juan J. Rios, A. Selva, V. Fonollosa
- P.234 FIRST PILOT STUDY OF T1 MAPPING MRI OF PERIPHERAL MUSCLE IN SYSTEMIC SCLEROSIS PATIENTS SHOWS DIFFUSE FIBROSIS THAT MAY ASSOCIATE WITH SUBCLINICAL CARDIAC INVOLVEMENT**  
R. [Dumitru](#), A. Goodall, David A. Broadbent, A. Kidambi, S. Plein, F. Del Galdo, A. Tan, J. Biglands, M. Buch

## IMAGING

- P.235 SEVERITY OF HAND VASCULAR INVOLVEMENT AS ASSESSED BY MRI DIGITAL ARTERY VOLUME INDEX (DAVIX®) PREDICTS WORSENING OF CLINICAL PARAMETERS AND PATIENT REPORTED OUTCOMES IN SCLERODERMA**  
F. Danzo, K. Gjeloshi, G. Lettieri, G. Abignano, M. Hinton, A. Dean, G. Cuomo, O. Kubassova, [F. Del Galdo](#)
- P.236 DEEP LEARNING FOR CALCINOSIS CUTIS QUANTIFICATION**  
A. Chandrasekaran, Z. Fu, A. Wang, S. Ren, R. Kraniski, I. Omar, [M. Hinchcliff](#)
- P.237 VISUALISATION OF THE ACTIVE CALCIFICATION PROCESS WITH 18-F SODIUM FLUORIDE PET/CT IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS WITH CALCINOSIS CUTIS IS FEASIBLE: A PILOT STUDY**  
G.M. Swart, I.M. Atzeni, E.M. Hogervorst, K. de Leeuw, M. Bijl, R. Bos, J. Westra, G.F. H. Diercks, H. van Goor, M.C. Bolling, R.H.J. A. Slart, [D.J. Mulder](#)
- P.238 CHANGE IN CALCINOSIS OVER 1 YEAR USING THE SCTC RADIOLOGIC SCORING SYSTEM FOR CALCINOSIS OF THE HANDS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
[V. Antonia](#), M. Chung, T. Rodriguez-Reyna, S. Proudman, M. Baron, F. Castelino, V. Hsu, S. Li, D. Fiorentino, K. Stevens, L. Chung
- P.239 COLOUR DOPPLER ULTRASONOGRAPHY IN DETECTION OF DIGITAL VASCULOPATHY IN SYSTEMIC SCLEROSIS**  
[O. Alekseeva](#), N. Yudkina, A. Volkov
- P.240 CROSS-VALIDATION AND COMPLEMENTARY VALUE OF OPTICAL COHERENCE TOMOGRAPHY AND HIGH FREQUENCY ULTRASOUND FOR THE ASSESSMENT OF SKIN DISEASE IN SYSTEMIC SCLEROSIS**  
[D. Temiz Karadag](#), G. Lettieri, V. Picerno, O. Gundogdu, M. Padula, G. Mennillo, A. Padula, F. Del Galdo, S. D'Angelo, G. Abignano
- P.241 RADIOLOGICAL HAND FINDING AND ITS CORRELATION WITH INTERNAL ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
[N. Abdolahi](#), F. Badiee, S. Tavassoli, M. Aghaei, M. Gharib, S. Livani

## VASCULAR

- P.242 LATE ONSET (OVER 65 YEARS) RAYNAUD'S PHENOMENON MAY IDENTIFY A PECULIAR SYSTEMIC SCLEROSIS' SUBSET?**  
[L. Urso](#), F. Cacciapaglia, F. Montini, V. Venerito, S. Duma, F. Iannone
- P.243 THE CORRELATION BETWEEN CARDIOPULMONARY PARAMETERS AND ARTERIAL STIFFNESS IN A CROSS-SECTIONAL STUDY IN SYSTEMIC SCLEROSIS**  
[G. Szucs](#), M. Kalasz, L. Bodoki, Z. Szekanez, S. Szamosi
- P.244 INFLUENCE OF EPOPROSTENOL INFUSIONS ON SERUM LEVEL OF ADIPOKINES IN SYSTEMIC SCLEROSIS**  
[A. Stochmal](#), J. Czuwara, M. Zaremba, L. Rudnicka
- P.245 SMOKING, RAYNAUD'S PHENOMENON, DIGITAL ULCERS AND SKIN THICKNESS IN THE WAIKATO SYSTEMIC SCLEROSIS COHORT**  
[K. Solanki](#), C. Silva, A. Schollum, D. White

- P.246 COPEPTIN AS A BIOMARKER OF PERIPHERAL MICROCIRCULATION DISORDERS IN SYSTEMIC SCLEROSIS**  
[M. Sikora](#), M. Chrabaszcz, M. Olszewska, L. Rudnicka
- P.247 SERUM LEVELS OF COL1A1 GENOMIC DNA AS A POTENTIAL DISEASE MARKER FOR PATIENTS WITH SYSTEMIC SCLEROSIS**  
[S. Sawamura](#), K. Makino, T. Makino, I. Kajihara, S. Fukushima, M. Jinnin, H. Ihn
- P.248 SUBCLINICAL ATHEROMATOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS UNDER 60 YEARS OLD**  
I. Sanz Pérez, [A. Guillén-del-Castillo](#), F. Martínez-Valle, O. Orozco Gálvez, C. Marcos Fosch, E. Callejas-Moraga, M. Riveiro Barciela, M. Roca Herrera, P. Gubern Prieto, V. Fonollosa-Pla, C. Simeón-Aznar
- P.249 NAILFOLD CAPILLAROSCOPY FINDINGS IN MIXED CONNECTIVE TISSUE DISEASE**  
[B. Samões](#), D. Fonseca, R. Vieira, T. Videira, J. Abelha-Aleixo, P. Pinto, M. Guerra
- P.250 A CANDIDATE GENE STUDY REVEALS ASSOCIATION BETWEEN A VARIANT OF THE SRP55 SPLICING FACTOR GENE AND SYSTEMIC SCLEROSIS (SSC)**  
E. Romano, M. Manetti, J. Kosalka, B. Fioretto, I. Rosa, E. Sticchi, S. Guiducci, S. Bellando-Randone, L. Ibba-Manneschi, [M. Matucci-Cerinic](#)
- P.251 LINKING US AND EUROPE: CONSENSUS BASED STANDARD EVALUATION OF DERMATOSCOPY AND NAILFOLD VIDEOCAPILLAROSCOPY, A EULAR STUDY GROUP ON MICROCIRCULATION IN RHEUMATIC DISEASES PROJECT**  
[M. Radic](#), T. Frech, M. Snow, L. Saketkoo, M. Cutolo, V. Smith
- P.252 INCIDENCE OF PULMONARY ARTERIAL HYPERTENSION AND SCLERODERMA RENAL CRISIS IN SYSTEMIC SCLEROSIS PATIENTS WITH DIGITAL ULCERS ON ENDOTHELIN ANTAGONIST RECEPTORS AND PHOSPHODIESTERASE-5 INHIBITORS**  
[M. Pestana-Fernandez](#), M. Rubio-Rivas, C. Tolosa-Vilella, A. Guillén-Del-Castillo, M. Freire, J. Vargas Hitos, J. Todolí Parra, A. Marín Ballvé, D. Colunga Argüelles, C. González-Echávarri Pérez, N. Ortego-Centeno, L. Triapiella Martínez, X. Pla Salas, A. Chamorro, I. Perales Fraile, M. Ruiz Muñoz, E. Callejas Moraga, V. Fonollosa Pla, C. Simeón Aznar, On behalf of RESCLE Investigators
- P.253 DECREASED CAPILLARY DENSITY AND ALTERED CAPILLARY MORPHOLOGY IS ASSOCIATED WITH INTERNAL ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
[G. Nagy](#), A. Kovács, T. Minier, C. Varijú, L. Czirájk, G. Kumánovics
- P.254 A PILOT STUDY OF PERFUSION AND OXYGENATION OF SYSTEMIC SCLEROSIS-RELATED DIGITAL (FINGER) ULCERS**  
[J. Manning](#), E. Marjanovic, T. Moore, G. Dinsdale, S. Wilkinson, M. Dickinson, A. Herrick, A. Murray
- P.255 PLASMA D-DIMER CONCENTRATION, MACROVASCULAR DISEASE AND MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
[L. Montolio Chiva](#), J. Alegre Sancho, M. Robustillo Villarino, M. Aguilar Zamora, E. Valls Pascual, D. Ybañez Garcia, A. Martínez Ferrer, A. Orenes Vera, I. Vázquez Gómez, I. Torner Hernández, V. Nuñez Monje, A. Sendra Garcia
- P.256 LOWER-LIMB ULCERS IN SYSTEMIC SCLEROSIS: A MONOCENTRIC RETROSPECTIVE STUDY OF 16 PATIENTS**  
[E. Montabone](#), A. Penatti, V. Data, G. Gardini, P. De Nigris, R. Carignola

## VASCULAR

- P.257** SIGNIFICANCE OF ANGIOTENSIN II/ACE2/ANGIOTENSIN-(1-7) AXIS FOR THE PATHOGENESIS OF SYSTEMIC SCLEROSIS  
B. Miziolek, B. Bergler-Czop, E. Kucharz, P. Kotyla, M. Kopec-Medrek, M. Widuchowska, M. Sienczyk, A. Lupicka-Slowik, R. Grzywa, L. Brzezinska-Wcislo
- P.258** MICRORNA EXPRESSION PROFILE IN MICROVASCULAR ENDOTHELIAL CELLS FROM THE SKIN OF SYSTEMIC SCLEROSIS  
T. Miyamura, K. Makino, M. Ide, T. Makino, H. Ihn
- P.259** MICROPARTICLES IN SYSTEMIC SCLEROSIS: A PROMISING BIOMARKER OF MICROVASCULAR DAMAGE?  
S. Maximiano, I. Azevedo Teixeira, C. Nunes Franca, L. Garcia Biagi, M. De Oliveira Izar, C. Kayser
- P.260** DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (SSC) SERUM SIGNIFICANTLY IMPAIRS LYMPHANGIOGENESIS IN VITRO  
M. Manetti, E. Romano, I. Rosa, B. Fioretto, S. Guiducci, S. Bellando-Randone, E. Pigatto, F. Cozzi, L. Ibbas-Manneschi, M. Matucci-Cerinic
- P.261** THERMOGRAPHY OF THE TOES IN PATIENTS WITH SYSTEMIC SCLEROSIS AND RAYNAUD'S PHENOMENON  
R. Lim, J. Manning, T. Moore, S. Wilkinson, G. Dinsdale, A. Herrick
- P.262** CLASSIFICATION OF FINGER PULP BLOOD FLOW AND ASSESSMENT OF RESISTANCE INDEX OF RADIAL ARTERY IN PATIENTS WITH SYSTEMIC SCLEROSIS AND HEALTHY CONTROLS  
A. Lescoat, A. Ballerie, F. Robin, M. De Saint Riquier, N. Belhomme, A. Perdriger, P. Jogo, G. Coiffier, C. Cazalets
- P.263** COMBINATION VASODILATOR THERAPY IMPROVES SKIN MICROVASCULAR BLOOD BUT DO NOT RESTORE ENDOTHELIAL FUNCTION IN SYSTEMIC SCLEROSIS  
C. Laurent, G. Hariri, J. Lavillegrand, S. Riviere, J. Joffre, H. Ait Oufella, A. Mekinian
- P.264** EPIGENETIC REGULATION MEDIATED REDUCTION IN THE EXPRESSION OF PROSTACYCLIN RECEPTOR (IP) AND PROSTACYCLIN SYNTHASE (PTGIS) IN SCLERODERMA SKIN, VASCULAR SMOOTH MUSCLE CELLS (VSMCs), AND MICROVASCULAR  
B. Kahaleh, Y. Wang, N. Altork
- P.265** PREDICTORS OF NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS; RESULTS FROM BEST-FITTED MODEL OF MULTIPLE REGRESSION ANALYSIS  
A. Javinani, F. Gharibdoost, A. Jamshidi, Z. Tamartash, H. Kavosi
- P.266** EXPLORING PATIENTS' PERCEPTIONS AND BELIEFS ON DIGITAL ULCER PATHOGENESIS IN SYSTEMIC SCLEROSIS  
M. Hughes, J. Pauling, J. Jones, C. Denton, R. Domsic, T. Frech, A. Herrick, D. Khanna, M. Matucci-Cerinic, L. McKenzie, L. Saketkoo, R. Goberman-Hill, A. Moore
- P.267** DIGITAL ULCER DEBRIDEMENT IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW  
M. Hughes, B. Alcaccer-Pitarch, A. Gheorghiu, E. Praino, R. Sandler, Y. Tavor, C. Bruni, M. Matucci-Cerinic
- P.268** A MULTI-CENTRE QUALITATIVE STUDY EXPLORING THE PATIENT EXPERIENCE OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS  
M. Hughes, J. Pauling, J. Jones, C. Denton, R. Domsic, T. Frech, A. Herrick, D. Khanna, M. Matucci-Cerinic, L. McKenzie, L. Saketkoo, R. Goberman-Hill, A. Moore
- P.269** EFFECT OF BIOFEEDBACK ON RAYNAUD'S SYNDROME IN SYSTEMIC SCLEROSIS PATIENTS  
R. Grekhoff
- P.270** INVOLUNTARY WEIGHT LOSS AND BEING UNDERWEIGHT ARE INDEPENDENTLY ASSOCIATED WITH AN INCREASED RISK OF RAYNAUD'S PHENOMENON IN BOTH MEN AND WOMEN  
A. Eman Abdulle, S. Arends, H. van Goor, L. Brouwer, A. M. van Roon, J. Westra, A. Herrick, K. de Leeuw, D. J. Mulder
- P.271** ELEVATED SERUM ENDOTHELIN -1 LEVELS IN PREECLAMPSIA ARE NOT ASSOCIATED WITH LONG-TERM MICROVASCULATURE DAMAGE AS EVALUATED BY NAILFOLD CAPILLAROSCOPY  
V. Dalm, J. Roeters Van Lennep, J. Duvekot
- P.272** THE ROLE OF CANNABIDIOL OIL IN THE MANAGEMENT OF SYSTEMIC SCLEROSIS DIGITAL ULCER-RELATED PAIN  
L. Magnani, A. Spinella, E. Cocchiara, F. Lumetti, G. Bajocchi, C. Salvarani, D. Giuggioli
- P.273** NEUTROPHIL TO LYMPHOCYTE RATIO AND MICROCIRCULATION IMPACT IN PATIENTS WITH SYSTEMIC SCLEROSIS – A CROSS-SECTIONAL STUDY  
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.274** NON-SCLERODERMA CAPILLAROSCOPIC PATTERN IN PATIENTS WITH RAYNAUD'S PHENOMENON AND POSITIVE ANTIBODIES FOR SYSTEMIC SCLEROSIS  
V. Bernardino, A. Rodrigues, M. Fernandes, A. Lladó, A. Panarra
- P.275** TREATMENT WITH INTRAVENOUS ILOPROST IN A MONOCENTRIC COHORT OF PATIENTS WITH SSC: COMPARISON BETWEEN TWO DIFFERENT THERAPEUTIC REGIMENS  
S. Barsotti, M. Di Battista, V. Venturini, S. Bilia, L. Puccetti, V. Lorenzoni, A. Della Rossa, G. Turchetti, M. Mosca
- P.276** RAYNAUD'S PHENOMENON IN RHEUMATIC DISEASES: INCIDENCE AND CLINICAL MANIFESTATIONS  
Z. Bagautdinova, I. Gaisin
- P.277** RAYNAUD'S PHENOMENON IN RHEUMATIC DISEASES AND PROSTANOID THERAPY WITH THE USE OF THE GENERALIZED INDICATOR OF RAYNAUD'S PHENOMENON MANIFESTATION  
Z. Bagautdinova, L. Gaisin, M. Giavatskikh
- P.278** ASSOCIATION OF CAPILLAROSCOPIC ABNORMALITIES WITH THICKENING OF THE CAROTID BULB IN PATIENTS WITH SYSTEMIC SCLEROSIS: COMPARISON BETWEEN MICRO AND MACRO-CIRCULATORY CHANGES  
C. Angelelli, I. Sciarra, M. Vasile, K. Stefanantoni, G. Pellegrino, G. Valesini, V. Riccieri
- P.279** HEMATOLOGICAL DISORDERS WITHIN SYSTEMIC SCLEROSIS: FREQUENCY AND CLINIC FEATURES  
B. Doskaliuk, R. Yatsyshyn

### RENAL

- P.280 CLINICAL FEATURES AND OUTCOME OF CHINESE PATIENTS WITH SCLERODERMA RENAL CRISIS: A CASE CONTROL STUDY**  
J. Zhou, D. Xu, Y. Hou, Q. Wang, M. Li, X. Zeng
- P.281 SCLERODERMA RENAL CRISIS IN THE RESCLE COHORT. ASSESSMENT OF PREDICTOR FACTORS AND CHANGE IN PREVALENCE OVER TIME**  
X. Pla Salas, C. Tolosa Vilella, I. Pons Martín del Campo, E. Callejas Moragas, A. Guillén del Castillo, J. Todolí Parra, M. Rodríguez Carballeira, A. Marín Ballvé, I. Perales Fraile, L. Sáez Comet, A. Argibay, A. Madroñero Vuelta, M. Sánchez García, C. González-Echavarrí, S. Sánchez Trigo, J. Sánchez-Redondo, R. Fernández de la Puebla G., V. Fonollosa Pla, C. Simeón Aznar, On behalf of RESCLE Investigators
- P.282 SCLERODERMA RENAL CRISIS OCCURS EARLY IN THE DISEASE COURSE: A CASE SERIES**  
M. Joubert, L. Otagne, P. Smets, R. Outh, O. Aumaitre, C. Garrouste, A. Lautrette, M. Hermet, M. Andre
- P.283 THE PATTERNS OF RENAL PATHOLOGY IN PATIENTS WITH SYSTEMIC SCLEROSIS RECEIVING RENAL BIOPSY: EXPERIENCE FROM A CHINESE TERTIARY MEDICAL CENTER**  
 X. Cao, Y. Hou, D. Xu, M. Li, Q. Wang, X. Zeng
- P.284 SENSORY-MOTOR NEUROPATHY AND RENAL IMPAIRMENT IN A SYSTEMIC SCLEROSIS PATIENT: RARE BUT NOT SO RARE?**  
K. Solanki, A. Schollum

### MUSCULOSKELETAL SYSTEM & REHABILITATION

- P.285 PSEUDOTUMORAL CALCINOSIS IN SYSTEMIC SCLEROSIS**  
E. Zanatta, M. Desportes, D. Hoang, J. Avouac, F. Antoine, Y. Allanore
- P.286 EFFICACY OF A TAILORED HAND/FACE REHABILITATION PROGRAM FOR SCLERODERMA PATIENTS: FINAL RESULTS OF A ONE-YEAR PROSPECTIVE CONTROLLED STUDY**  
M. Spiritovic, H. Smucrova, S. Oreska, H. Storkanova, B. Hermankova, P. Cesak, A. Rathouska, O. Ruzickova, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcik
- P.287 CLINICAL CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND SYMPTOMATIC SUBCUTANEOUS CALCINOSIS**  
Y. Shirai, M. Kuwana
- P.288 ASSESSING SKELETAL MUSCLE MASS WITH ULTRASOUND IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
A. Akdogan, A. Sari, M. Esme, L. Kilic, G. Aycicek, M. Halil
- P.289 CLINICAL, PARACLINICAL AND RADIOLOGICAL ASSESSMENT OF THE MUSCULOSKELETAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS**  
H. Poormoghim, N. Azarban, A. Javadzadeh, E. Andalib, I. Mohseni, A. Jalali
- P.290 PREVALENCE OF OSTEOPOROSIS IN SYSTEMIC SCLEROSIS - A POPULATION BASED STUDY**  
K. Lillpers, I. Bartosik, D. Wuttge, K. Andréasson, K. Åkesson, R. Hesselstrand

- P.291 PHYSICAL THERAPY IN SYSTEMIC SCLEROSIS: PERSPECTIVES FROM PATIENTS AND THEIR PHYSIOTHERAPISTS**  
S. Liem, N. Van Leeuwen, E. Van Den Ende, L. De Punder, R. Schriemer, J. Spierings, M. Vonk, T. Vliet Vlieland, J. de Vries-Bouwstra
- P.292 BONE MINERAL DENSITY AND TRABECULAR BONE SCORE ASSESSMENT IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY**  
A. Lescoat, M. Leroy, G. Coiffier, C. Cazalets, N. Belhomme, A. Ballerie, F. Robin, P. Jegou, P. Guggenbuhl
- P.293 THE EFFICACY OF A CONCISE SELF-MANAGEMENT PROGRAM FOR HANDS IN SSC – AN OBSERVATIONAL CASE-CONTROL STUDY**  
S. Landim, M. De Barros Bértolo, Janet L. Poole, A. Del Rio, E. De Paiva Magalhães
- P.294 MUSCULOSKELETAL MANIFESTATIONS OF SYSTEMIC SCLEROSIS: FOCUSING ON RIB OSTEOLYSIS**  
J. Jun, J. Ryu, T. Kim, S. Lee
- P.295 REDUCED CIRCULATING LEVELS OF INORGANIC PYROPHOSPHATE ARE ASSOCIATED WITH ECTOPIC CALCIFICATION IN SCLERODERMA SPECTRUM DISORDERS**  
V. Hsu, N. Schlesinger, Q. Li, J. Varga
- P.296 EFFECTS OF A HOME-BASED PULMONARY REHABILITATION PROGRAM, IN PATIENTS WITH INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: A PILOT STUDY**  
S. Faverzani, A. Ariani, A. Becciolini, F. Nocera, F. Mozzani, D. Santilli, L. Monica, L. Barone, V. Alfieri, E. Crisafulli, M. Marvisi, M. Bigliardi, M. Tommasi, C. Micheli, L. Montinaro, G. Scopelliti, N. Salati
- P.297 IF YOU DON'T USE IT, YOU LOSE IT': REHABILITATION OF FINGER DEXTERITY AND ABILITY TO PERFORM ACTIVITIES OF DAILY LIVING IN SYSTEMIC SCLEROSIS**  
E. Eusterwiemann, M. Anderson, M. Robinson, Gabor J. Barton
- P.298 SYSTEMIC SCLEROSIS OVERLAP SYNDROME IN 10 YEARS**  
O. Desinova, M. Starovoytova, L. Ananieva
- P.299 COMPARISON OF RELAPSING POLYCHONDRIITIS PATIENTS WITH/ WITHOUT ARTHROPATHY ONSET**  
 X. Cao, Y. Hou, D. Xu, M. Li, Q. Wang, X. Zeng

### GASTROINTESTINAL/NUTRITION

- P.300 SEVERITY AND EVOLUTION OF GASTRO-INTESTINAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS IN TWO LARGE AND INDEPENDENT COHORTS**  
N. Van Leeuwen, H. Fretheim, Ø. Molberg, T. Huizinga, J. De Vries-Bouwstra, A. Hoffman-Vold
- P.301 METABOLITES DERIVED FROM GUT MICROBIOTA IN THE BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Sikora, A. Stec, M. Olszewska, L. Rudnicka

## GASTROINTESTINAL/NUTRITION

- P.302** **BODY COMPOSITION IN SCLERODERMA PATIENTS AND THE ASSOCIATION WITH THE DISEASE ACTIVITY, SYSTEMIC INFLAMMATORY CYTOKINES/CHEMOKINES, LIPID PROFILE AND NUTRITION STATUS**  
S. Oreska, M. Spiritovic, P. Cesak, M. Cesak, H. Storkanova, H. Smucrova, B. Hermankova, O. Ruzickova, K. Pavelka, L. Senolt, J. Vencovsky, R. Becvar, M. Tomcik
- P.303** **SURVEY ON DYSPHAGIA USING SIMPLE QUESTIONNAIRE EAT-10 IN PATIENT WITH SYSTEMIC SCLEROSIS**  
T. Naganawa, S. Yoshida, A. Kuwabara, M. Sawada, N. Watanabe, M. Suzuki, A. Umeda, K. Ashihara, M. Kurimizawa, D. Hirano, Y. Inamoto, T. Hashimoto, J. Nishino, S. Fukaya, S. Sibata, E. Saitoh, H. Yasuoka
- P.304** **ESOPHAGEAL INVOLVEMENT AND DETERMINANTS OF PERCEPTION OF ESOPHAGEAL SYMPTOMS AMONG EAST ASIAN PEOPLE WITH SYSTEMIC SCLEROSIS IN THE ERA OF HIGH-RESOLUTION MANOMETRY**  
H. Kim, W. Choi, M. Kim, T. Lee
- P.305** **PREVALENCE OF GASTROESOPHAGEAL DISEASE IN SYSTEMIC SCLEROSIS AND ITS POTENTIAL IMPACT ON LUNG DISEASE**  
S. Kafaja, T. Shagroni, R. Saggar, A. Aly, I. Valera, P. Clements, J. Conklin, D. Furst
- P.306** **PREDICTORS OF SIGNIFICANT WEIGHT LOSS IN SYSTEMIC SCLEROSIS - A STUDY FROM THE EULAR SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE**  
M. Hughes, C. Heal, J. Wilkinson, Eustar Investigators
- P.307** **GASTROINTESTINAL INVOLVEMENT IS ASSOCIATED WITH DEPRESSION AND ANXIETY IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
A. Gheorghiu, C. Vrancianu, B. Busuioc, C. Draganescu, A. Briceag, L. Macovei, M. Sasu, I. Ancuta, V. Stoica, M. Bojinca, C. Mihaï
- P.308** **RELATIONSHIP BETWEEN INTERSTITIAL PULMONARY DISEASE AND ESOPHAGIC PATHOLOGY IN SYSTEMIC SCLEROSIS. STUDY OF ONE COHORT OF 92 PATIENTS**  
P. García De La Peña Lefebvre, G. González Arribas, M. Novella Navarro, J. González Martín
- P.309** **MALNUTRITION IN SYSTEMIC SCLERODERMA: IS 'THE 15 PERCENT' RULE APPLICABLE?**  
A. Burlui, M. Graur, A. Gherasim, A. Cardoneanu, L. Macovei, E. Rezus
- P.310** **GASTROPARESIS IN SYSTEMIC SCLEROSIS PATIENTS: CLINICAL CHARACTERISTICS**  
R. Brun, A. Balbir-Gurman, Y. Braun-Moscovici
- P.311** **DURATION AND SYSTEMIC SCLEROSIS SUBTYPE ARE ASSOCIATED WITH DIFFERENT GUT MICROBIOME PROFILES**  
Y. Braun-Moscovici, S. Ben Simon, K. Dolnikov, S. Guries, D. Markovits, Y. Tavor, K. Toledano, M. Nahir, A. Balbir-Gurman, O. Koren
- P.312** **BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS IN A COHORT OF PATIENTS WITH SSC AND IMPLICATION WITH CLINICAL ACTIVITY PARAMETERS**  
M. Di Battista, A. Rossi, S. Barsotti, A. Monaco, A. Della Rossa, M. Mosca

- P.313** **SARCOPENIA IN PATIENTS WITH SYSTEMIC SCLEROSIS - PILOT STUDY FROM A SINGLE CENTER**  
M. Baresic, D. Ljubas Kelecic, B. Karanovic, I. Karas, Z. Krznaric, B. Anic
- P.314** **SYSTEMIC SCLEROSIS AND VITAMIN D DEFICIENCY**  
L. Athanassiou, I. Kostoglou, E. Devetzi, M. Gatsiou, P. Tsakiridis, M. Mavroudi, A. Tzanavari, P. Athanassiou
- P.315** **FEATURES OF DAMAGE OF THE GASTROINTESTINAL TRACT IN PATIENTS WITH SYSTEMIC SCLERODERMA**  
V. Aleksandrov, L. Shilova, A. Aleksandrov, I. Zborovskaya

## GENDER RELATED ISSUES

- P.316** **PREGNANCY OUTCOME IN SYSTEMIC SCLEROSIS: IS THERE ANY CORRELATION BASED ON TOPO I, DISEASE SUBTYPES AND DISEASE ONSET?**  
H. Poormoghim, M. Shakerian, E. Andalib, Z. Raufi, A. Jalali
- P.317** **CLINICAL CHARACTERISTICS OF MALE PATIENTS WITH SYSTEMIC SCLEROSIS; RESULTS FROM IRANIAN SYSTEMIC SCLEROSIS REGISTRY**  
A. Javani, F. Gharibdoost, A. Jamshidi, Z. Tamartash, M. Mahmoudi, H. Kavosi
- P.318** **OBSTETRIC COMPLICATIONS PRIOR TO SYSTEMIC SCLEROSIS DIAGNOSIS**  
M. Chung, H. Zhao, K. Kolstad, P. Manwani, M. Dontsi, D. Postlethwaite, J. Simard, L. Chung
- P.319** **ARE SILICON IMPLANTS ASSOCIATED SYSTEMIC SCLEROSIS (SSC) AND IDIOPATHIC SSC DIFFERENT ENTITIES?**  
Y. Braun-Moscovici, M. Braun, D. Markovits, K. Toledano, Y. Tavor, A. Rozin, K. Dolnikov, N. Finkelstein-Yeshurun, S. Guries, M. Nahir, A. Balbir-Gurman
- P.320** **FAVORABLE OUTCOME OF PLANNED PREGNANCIES IN SYSTEMIC SCLEROSIS PATIENTS DURING STABLE DISEASE**  
Y. Braun-Moscovici, D. Markovits, V. Shataylo, A. Avshalom-Mashiah, M. A. Nahir, A. Balbir-Gurman

## RECENT ADVANCES IN THERAPY (CASE SERIES FOR NEW TREATMENT)

- P.321** **THE EFFICACY AND SAFETY OF RITUXIMAB IN 27 CASES OF TREATMENT RESISTANT SYSTEMIC SCLEROSIS WITH SEVERE DISEASE: FAVORABLE EFFECT ON DISEASE ACTIVITY**  
Y. Yalcinkaya, B. Artim Esen, S. Amikishiyev, N. Aliyeva, A. Gul, L. Ocal, M. Inanc
- P.322** **PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND EVENT-FREE SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENT**  
M. Vonk, S. Van Bijnen, M. Boonstra, E. Van Den Ende, L. Kroft, B. Geurts, M. Snoeren, A. Schouffoer, J. Spierings, J. van Laar, T. Huizinga, A. Voskuyl, W. van der Velden, F. van den Hoogen, J. de Vries-Bouwstra

### RECENT ADVANCES IN THERAPY (CASE SERIES FOR NEW TREATMENT)

- P.323 EFFECTIVENESS OF RITUXIMAB IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS. A MULTICENTER ANALYSIS**  
 I. Vázquez Gómez, J. Lluch Pons, F. Narváez García, M. Aguilar Zamora, L. Montolio Chiva, A. Orenes Vera, E. Flores Fernández, A. Martínez Ferrer, E. Valls Pascual, D. Ybáñez García, I. Torner Hernández, V. Núñez Morje, A. Sendra García, J. Alegre Sancho
- P.324 AMINAPHTONE EFFICACY IS NOT INFLUENCED BY DIFFERENT PHARMACOLOGICAL BACKGROUNDS IN SYSTEMIC SCLEROSIS PATIENTS**  
 A. Sulli, E. Gotelli, F. Goegan, B. Ruaro, C. Pizzorni, S. Paolino, M. Cutolo
- P.325 COMBINATION THERAPY OF RITUXIMAB AND MYCOPHENOLATE MOFETIL FOR SEVERE SYSTEMIC SCLEROSIS – SAFETY AND EFFICACY**  
 D. Rimar, A. Silawi, I. Rosner, M. Rozenbaum, K. Kali, N. Boulman, G. Slobodin
- P.326 FIRST CASE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS IN ESTONIA**  
 E. Pärsik, E. Raussi, D. Loigom, K. Palk, E. Ojassalu, P. Tuvik, Ä. Roose
- P.327 RESPONSIVENESS TO CHANGE OF THE MODIFIED RODNAN SKIN SCORE IN A PHASE I/II DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL**  
 V. Nagaraja, E. Bush, R. Lafyatis, D. Khanna
- P.328 COMPARISON OF SAFETY AND EFFICACY BETWEEN DIFFERENT BIOLOGIC THERAPIES IN SYSTEMIC SCLEROSIS**  
 D. Lobo-Prat, A. Millán, L. Sainz, H. Park, B. Magallares, P. Moya, S. Fernández, S. Ros, C. Díaz-Torrè, A. Laiz, A. García-Guillén, S. Jeria, H. Corominas, I. Castellví
- P.329 STELLATE BLOCKADE COMBINED TO ILOPROST AS NEW TREATMENT OPTION FOR IMPROVEMENT OF ISCHAEMIC SYMPTOMS IN PATIENTS WITH SYSTEMIC SCLEROSIS – FIRST INTERIMS ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY**  
 F. Höckestaller, U. Henkemeier, M. Zimmermann, H. Burkhardt, F. Behrens, U. Drott, M. Köhm
- P.330 BOTULINUM TOXIN: A PROMISING TREATMENT MODALITY FOR OROFASCIAL DIFFICULTIES IN SCLERODERMA PATIENTS**  
 S. Kafaja, P. Clements, D. Furst, D. Zinati, K. Omrani
- P.331 THERAPY WITH RITUXIMAB IN SYSTEMIC SCLEROSIS (SSC): A SINGLE CENTRE COHORT STUDY**  
 I. Jandova, N. Venhoff, J. Thiel, C. Glaser, R. Voll
- P.332 CHANGES IN ANTINUCLEAR ANTIBODY TITERS, ASSOCIATED WITH SYSTEMIC SCLEROSIS, DURING LONG-TERM RITUXIMAB THERAPY**  
 L. Garzanova, L. Ananyeva, O. Koneva, O. Ovsyannikova, O. Desinova, M. Starovoytova, S. Glukhova, M. Cherkasova, A. Alexankin
- P.333 POSSIBLE BENEFIT OF TADALAFIL CREAM FOR THE TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS**  
 A. Fernandez-Codina, M. Kazem, J. Pope

- P.334 EFFECTS OF RITUXIMAB THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
 M. Starovoytova, O. Desinova, L. Ananieva, L. Garsonova, O. Koneva, O. Ovsyannikova
- P.335 EFFICACY OF SELEXIPAG ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: ANALYSIS OF A PRELIMINARY STUDY**  
 N. Del Papa, S. Bilia, D. Giannini, A. Grimaldi, E. Quarta, F. Pignataro, A. Minniti, W. Maglione, P. Migliorini, A. Tavoni
- P.336 RITUXIMAB IN SYSTEMIC SCLEROSIS MANAGEMENT: MULTICENTRIC CLINICAL EXPERIENCE AND LONG-TERM FOLLOW-UP**  
 F. Lumetti, L. Magnani, A. Spinella, E. Cocchiara, G. Bajocchi, C. Ferri, C. Salvarani, D. Giuggioli
- P.337 INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS: A MULTICENTER EXPERIENCE**  
 J. Tandaiapan, A. Guillen, P. Carreira, F. Narváez, M. Rubio-Rivas, V. Ortiz-Santamaría, C. De La Puente, J. Pego, R. García-Vicuña, A. Pros, C. Galisteo, B. Atienza-Mateo, J. Lluch, R. Blanco, C. Simeón-Aznar, I. Castellví
- P.338 SAFETY AND EFFECTIVENESS OF ABATACEPT IN SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE**  
 I. Castellví, M. Elhai, C. Bruni, P. Airò, S. Jordan, L. Beretta, V. Codullo, C. Montecucco, M. Bokarewa, F. Iannone, A. Balbir, V. Hsu, O. Distler, M. Matucci-Cerinic, Y. Allanore
- P.339 SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY**  
 C. Campochiaro, G. De Luca, M. Lazzaroni, E. Zanatta, S. Bosello, M. De Santis, A. Cariddi, C. Bruni, C. Selmi, E. Gremese, M. Matucci-Cerinic, A. Doria, P. Airò, L. Dagna
- P.340 THE PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL IN SYSTEMIC SCLEROSIS VARIES MANIFOLD BETWEEN PATIENTS AND IS ASSOCIATED WITH GASTROINTESTINAL INFLAMMATION**  
 K. Andréasson, K. Neringer, D. Henrohn, A. Mårtensson, D. Wuttge, R. Hesselstrand
- P.341 EFFECTIVE ANTI-FIBROTIC THERAPY FOR SYSTEMIC SCLEROSIS: DUAL-TARGETING OF PERIPHERAL CANNABINOID-1 RECEPTORS AND INDUCIBLE NO SYNTHASE**  
 R. Cinar, J. K. Park, C. N. Zawatsky, J. Abdalla, M. Iyer, G. Kunos

### PEDIATRIC SCLERODERMA

- P.342 PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018**  
 I. Foeldvari, K. Torok, J. Anton, M. Blakley, T. Constantine, M. Curran, M. Cutolo, C. Denton, K. Figelstone, B. Heinrichs, A. Höger, F. Ingegnoli, S. Li, D. Nemcova, C. Orteu, C. Pilkington, V. Smith, A. Stevens, D. Khanna, D. Furst
- P.343 NO DISEASE PROGRESSION AFTER 36 MONTHS FOLLOW UP IN THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT**  
 I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, M. Terrieri, R. Cimaz, T. Avcin, M. Katsikas, D. Nemcova, M. Santos, J. Brunner, T. Kallinich, M. Kostik, K. Minden, A. Patwardhan, K. Torok, N. Helmus



## PEDIATRIC SCLERODERMA

- P.344 UNDER DETECTION OF INTERSTITIAL LUNG DISEASE IN JUVENILE SYSTEMIC SCLEROSIS (JSSC) UTILIZING PULMONARY FUNCTION TESTS. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT**  
 I. Foeldvari, B. Hinrichs, K. Torok, M. Maria Jose, O. Kasapcopur, A. Adrovic, V. Stanevicha, F. Sztajn bok, M. Terrieri, E. Alexeeva, J. Anton, M. Katsikas, V. Smith, T. Avcin, R. Cimaz, M. Kostik, T. Lehman, W.-A. Sifuentes-Giraldo, N. Helmus
- P.345 HOW THE ADULT CRISS WORKS IN PEDIATRIC JSSC PATIENTS - RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT**  
 J. Klotsche, I. Foeldvari, O. Kasapcopur, A. Adrovic, K. Torok, V. Stanevicha, J. Anton, R. Cimaz, W.-A. Sifuentes-Giraldo, M. Terrieri, F. Sztajn bok, C. Battagliotti, L. Bernston, D. Eleftheriou, G. Horneff, F. Nuruzaman, N. Helmus
- P.346 IS THE PRESENTATION AND SEVERITY DIFFERENT OF THE JUVENILE DIFFUSE AND LIMITED SUBTYPE SYSTEMIC SCLEROSIS? RESULTS OF JUVENILE SCLERODERMA INCEPTION COHORT**  
 I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, K. Torok, V. Stanevicha, M. Terrieri, F. Sztajn bok, E. Alexeeva, J. Anton, B. Feldman, M. Katsikas, V. Smith, T. Avcin, R. Cimaz, M. Kostik, T. Lehman, W.-Alberto Sifuentes-Giraldo, N. Vasquez-Canizares, N. Helmus

## SCLEROSING SKIN DISEASES (LOCALIZED SCLERODERMA)

- P.347 A CASE REPORT OF MICROSURGICAL ALAR RECONSTRUCTION USING VASCULARIZED HELICAL RIM FLAPS FOR LOCAL SCLEROSIS PATIENT**  
 H. Xiao
- P.348 LOW DOSE NALOXONE FOR THE MANAGEMENT OF PRURITUS IN PATIENTS WITH SCLERODERMA**  
 I. Vidorchick, J. Berookhim, Y. Levy
- P.349 SCLEREDEMA ADULTORUM OF BUSHKE IS ASSOCIATED WITH A HIGHER PREVALENCE OF STROKE AND DYSLIPIDEMIA COMPARED TO DIABETICS WITHOUT SCLEREDEMA**  
 C. Varju, V. Csonka, B. Bódis, N. Farkas, D. Kovács, L. Czirják
- P.350 COEXISTENCE OF SYSTEMIC SCLEROSIS AND MORPHEA**  
 A. Vanhaecke, L. Heeman, H. Callens, M. Cutolo, F. De Keyser, S. De Schepper, S. Nguyen, J. Guter muth, V. Smith
- P.351 EFFECTIVENESS OF TOPICAL SODIUM TIOSULFATE FOR THE TREATMENT OF CALCINOSIS-ASSOCIATED CUTANEOUS ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
 I. Torner Hernández, A. Sendra García, V. Nuñez Monje, L. Montolio Chiva, A.V. Orenes Vera, I. Vazquez Gomez, E. Flores Fernández, M. Aguilar Zamora, E. Valls Pascual, A. Martinez Ferrer, D. Ybañez García, J. Alegre Sancho
- P.352 CORRELATION OF EXPRESSION OF TLR7 AND MIRNA-146A GENES AND FIBROSIS IN PERIPHERAL BLOOD AND SKIN SAMPLES OF SSC PATIENTS**  
 V. Spasovski, M. Vreca, M. Andjelkovic, M. Stojilkovic, A. Skakic, K. Klaassen, A. Zekovic, N. Damjanov, S. Pavlovic

- P.353 TOCILIZUMAB AS TREATMENT FOR CUTANEOUS INVOLVEMENT IN SYSTEMIC SCLEROSIS: A SERIES OF 3 CASES**  
 E. Ortiz-Sanjuán, C. Alcañiz, I. Cánovas, I. Chalmeta, M. De La Rubia, J. Frago, R. González, L. González, E. Grau, S. Leal, I. Martínez, C. Nájera, R. Negueroles, C. Páez, J. Oller, E. Vicens, J. Ivorra, J. Román-Ivorra
- P.354 IL-16 EXPRESSION IS INCREASED IN THE SKIN AND SERA OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
 T. Makino, K. Makino, S. Sawamura, S. Shimada, T. Yamashita, M. Hayashi, T. Miyamura, S. Ishimatsu, H. Ihn
- P.355 LOCO-REGIONAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW**  
 I. Costedoat, M. Masson, T. Barnette, E. Lazaro, P. Duffau, C. Richez, J. Seneschal, M. Truchetet
- P.356 ANALYSIS OF HISTOPATHOLOGICAL CUTANEOUS ALTERATIONS IN SYSTEMIC SCLEROSIS**  
 E. Cocchiara, A. Spinella, E. Veronesi, M. Pignatti, F. Lumetti, L. Magnani, G. Bajocchi, G. De Santis, C. Salvarani, M. Dominici, D. Giuggioli
- P.357 EOSINOPHILIC FASCIITIS, A MONOCENTRIC RETROSPLECTIVE STUDY OF 30 PATIENTS**  
 M. Thiebaut, B. Chaigne, N. Dupin, O. Mangin, P. Cohen, J. London, A. Regent, N. Costedoat-Chalumeau, C. Lejeune, F. Authier, L. Mouthon
- P.358 PROTEOMIC AND TRANSCRIPTOMIC ANALYSIS OF HUMAN EOSINOPHILIC FASCIITIS FIBROBLASTS**  
 B. Chaigne, C. Fernandez, M. Le Gall, P. Chafey, B. Saintpierre, V. Salnot, F. Guillonnet, C. Le Jeune, L. Mouthon
- P.359 CHARACTERIZATION OF SCLERODERMA PATIENTS ACCORDING TO RS2 AND KU ANTIBODIES**  
 J. Caballero Castro, A. Guillén Del Castillo, E. Callejas Moraga, D. Colunga Argüelles, L. Sáez Comet, M. Rubio Rivas, A. Argibay, J. Vargas Hitos, J. Todolí Parra, I. Perales Fraile, C. Tolosa Vilella, A. Marin Ballvé, A. Madroñero Vuelta, M. Sánchez García, N. Ortego-Centeno, G. Espinosa, M. Rodríguez Carballera, V. Fonollosa Pla, C. Simeón Aznar, On behalf of RESCLE Investigators
- P.360 POTENTIAL BIOMARKERS OF SKIN CHANGES IN SYSTEMIC SCLEROSIS**  
 R. Becvar, H. Storkanova, B. Sumova, M. Spiritovic, S. Oreska, L. Senoit, M. Tomcik
- P.361 PREVALENCE AND ASSOCIATES OF CANCER IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS ATTENDING A SINGLE CENTRE**  
 A. Agnihotri, J. Manning, S. Wilkinson, M. Samaranyaka, A. L Herrick

## EMERGING THERAPIES (PRE-CLINICAL)

- P.362 AN ORALLY AVAILABLE HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING PULMONARY AND DERMAL FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS**  
 H. Arozenius, L. Pettersson, G. Ekström, C. Wenglé

## EMERGING THERAPIES (PRE-CLINICAL)

- P.363 HSP90 INHIBITOR 17-DMAG REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS IN MICE INDUCED BY BLEOMYCIN**  
H. Storkanova, L. Storkanova, S. Oreska, M. Spiritovic, B. Hermankova, R. Becvar, K. Pavelka, J. Vencovsky, J. Distler, L. Senolt, [M. Tomcik](#)
- P.364 VITAMIN D DOWNREGULATES PRO-FIBROTIC MOLECULES ASSOCIATED WITH SYSTEMIC SCLEROSIS: ALPHA-SMA AND PSMAD2/3**  
[A. Rodrigues De Almeida](#), M. De Oliveira Gonçalves, E. Gustavo Constantino Cunha, J. De Melo Gomes, A. Tavares Dantas, R. Silva Guimarães Gonçalves, A. Luzia Branco Pinto Duarte, M. Barreto De Melo Régio, M. Cristiny Pereira, M. D. Lima De Oliveira, M. Galdino Da Rocha Pitta
- P.365 CADHERIN 11 AND COLLAGEN I IN A SCLERODERMA FIBROTIC MODEL AND EFFECT OF MECHANOSENSING AND INFLAMMATORY INHIBITORS ON THEIR EXPRESSION**  
[A. Mujkanovic](#), T. Lim, X. Shiven, B. Ahmed Abdi, G. Martin, H. Lopez, D. Abraham, C. Denton, R. Stratton
- P.366 VASCULARIZED HUMAN SKIN EQUIVALENTS AS A NOVEL IN VITRO MODEL OF SKIN FIBROSIS AND PLATFORM FOR TESTING OF ANTIFIBROTIC DRUGS**  
[A. Matei](#), C. Chen, L. Kiesewetter, A. Györfi, Y. Li, T. Trinh-Minh, X. Xu, T. Cuong, Toin H. Van Kuppevelt, J. Hansmann, A. Jungel, G. Schett, F. Groeber-Becker, J.H.W. Distler
- P.367 IMPACT OF JAK INHIBITORS ON MACROPHAGE POLARISATION: PERSPECTIVES FOR SYSTEMIC SCLEROSIS**  
[A. Lescoat](#), A. Ballerie, M. Lelong, C. Morzadec, S. Jouneau, P. Jegu, L. Vernhet, O. Fardel, V. Lecreur
- P.368 SECUKINUMAB AND METFORMIN AMELIORATE BLEOMYCIN INDUCED DERMAL FIBROSIS**  
C. Celik, A. Karatas, B. Oz, Z. Akar, E. Etem, A. Dagli, [S. Koca](#)
- P.369 BOTULINUM TOXIN IN THE MANAGEMENT OF RAYNAUD'S PHENOMENON**  
[D. Ennis](#), Z. Ahmad, K. Devakandan, M. Anderson, S. Johnson
- P.370 TRAINED IMMUNITY MODULATES INFLAMMATION-INDUCED FIBROSIS**  
[M. Jeljeli](#), L. Gama Coelho Riccio, L. Doridot, C. Chêne, C. Nicco, S. Chouzenoux, Q. Deletang, Y. Allanore, N. Kavian, F. Batteux
- P.371 2-CARBA-CPA AMELIORATES EXPERIMENTAL DERMAL FIBROSIS BY SUPPRESSING THE ACTIVATION OF FIBROBLASTS AND IMMUNE CELLS**  
[T. Higuchi](#), K. Takagi, A. Tochimoto, T. Norose, I. Masuda, T. Sawada, N. Shibata, T. Morohoshi, M. Harigai, Y. Kawaguchi
- P.372 INHIBITION OF IL-4 AND IL-13 PRODUCTION BY A NEW THIAZOLIDINE DERIVATIVE (SF-34) IN PBMC FROM SYSTEMIC SCLEROSIS PATIENTS**  
[M. Galdino Da Rocha Pitta](#), [A. Rodrigues De Almeida](#), A. Tavares Dantas, E. Gustavo Constantino Cunha, M. Bezerra Correia, L. De Azevedo Valadares, M. De Oliveira Gonçalves, J. De Melo Gomes, M. Barreto De Melo Régio, I. Da Rocha Pitta, M. Galdino Da Rocha Pitta, A. Luzia Branco Pinto Duarte, D. Saes Parra Abdalla

- P.373 CXCL5 AMELIORATES SYSTEMIC SCLEROSIS VIA SUPPRESSING HELPER T CELL-MEDIATED IMMUNE RESPONSE**  
[X. Fan](#), D. Guo, C. Ng, A. Law, K. Lim, J. Thumboo, W. Hwang, A. Low
- P.374 ADIPOSE-DERIVED MESENCHYMAL STEM CELLS CONDITIONED MEDIUM INHIBITS PRO-FIBROTIC ACTIVITY OF SSC FIBROBLASTS AND INDUCE A PRO-ANGIOGENIC PHENOTYPE**  
[N. Del Papa](#), M. Lorini, V. Carbonelli, F. Pignataro, A. Minniti, F. Campanaro, C. Verrastro, W. Maglione
- P.375 PED5 INHIBITOR SILDENAFIL COUNTERACTS THE DNA DAMAGE INDUCED BY OXIDATIVE STRESS IN SCLERODERMA FIBROBLASTS**  
L. Di Luigi, G. Duranti, A. Antonioni, P. Sgro', R. Ceci, D. Caporossi, S. Sabatini, F. Del Galdo, A. Lenzi, I. Dimauro, [C. Antinozzi](#)
- P.376 CONSTITUTIVE ACTIVATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 IN LUNG AND SKIN OF TRANSGENIC MOUSE - A NEW MODEL OF SCLERODERMA**  
[G. Bogatkevich](#), I. Atanelishvili, T. Akter, A. Bogatkevich, R. Silver

## CASE REPORTS

- P.377 NEWLY DIAGNOSED SYSTEMIC SCLEROSIS IN AFRICAN PATIENT DURING VISIT IN SWEDEN – ETHICAL DILEMMAS OF MEDICAL CARE AND FOLLOW-UP**  
[E. Thomaidi](#)
- P.378 A RARE PRESENTATION OF RENAL IMPAIRMENT IN DIFFUSE SYSTEMIC SCLEROSIS PATIENT**  
[K. Solanki](#), A. Schollum, D. Lamont, D. White
- P.379 EXTENSIVE CALCINOSIS CUTIS IN A PATIENT WITH SYSTEMIC SCLEROSIS**  
[T. Simopoulou](#), M. Vlychou, D. Bogdanos, L. Sakkas
- P.380 GAVE - AN OFTEN OVERLOOKED COMPLICATION IN SYSTEMIC SCLEROSIS**  
[R. Shukla](#), A. Herrick
- P.381 THE RENAL CRISIS CONUNDRUM**  
[S. Shoela](#), A. Beltagy
- P.382 PERICARDIAL INVOLVEMENT AND CREST SYNDROME**  
[Q. Selmi](#), I. Saoud, M. Lajmi, I. Chaabane, R. Amri, H. Tounsi, W. Garbouj, B. Ben Ammou, J. Ouaili, R. Jazi
- P.383 A CASE OF SYSTEMIC SCLEROSIS & NEUROSARCOIDOSIS**  
[A. Schnell](#), A. Gaffo
- P.384 GRANULOMATOUS UVEITIS REVEALING SCLEROMYOSITIS**  
[I. Saoud](#), W. Garbouj, O. Selmi, R. Amri, H. Tounsi, M. Lajmi, I. Chaabane, Z. Alaya, B. Ben Ammou, J. Ouaili, R. Jazi
- P.385 SYSTEMIC SCLEROSIS – A POLYSEGMENTAL REFLEX DYSTROPHY – TREATED BY MATRIX RHYTHM THERAPY. CASE REPORT SEVEN YEARS AFTER DIAGNOSIS**  
U. Randoll, [Y. Largjader](#)

### EMERGING THERAPIES (PRE-CLINICAL)

- P.386 SEVERE AORTIC ROOT DILATATION IN PSS REVERSING WITH AGGRESSIVE MEDICAL THERAPY**  
*C. Rajapakse*
- P.387 SYSTEMIC SCLEROSIS INDUCED BY CNS STIMULANTS FOR ADHD: A CASE SERIES AND REVIEW OF THE LITERATURE**  
*K. Meridor, Y. Levy*
- P.388 AN UNUSUAL EOSINOPHILIC FASCIITIS OCCURRING IN A FITNESS TRAINER: COINCIDENCE OR RELATIONSHIP?**  
*E. Meleddu, F. Renzullo, P. Mascia, A. Cauli, A. Vacca*
- P.389 SYSTEMIC SCLEROSIS AND NEPHROTIC SYNDROME: AN UNUSUAL ASSOCIATION**  
*P. Martins, E. Dourado, F. Marques, S. Jorge, J. Lopes, J. Guerra, J. Fonseca, I. Cordeiro, C. Resende*
- P.390 A CASE REPORT OF SYSTEMIC SCLERODERMA WITH POSITIVE ANTI-KU AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES**  
*M. Lajmi, I. Saoud, O. Selmi, H. Tounsi, I. Chaabane, W. Garbouj, Z. Alaya, B. Ben Ammou, R. Jazi, O. Jihen, R. Amri*
- P.391 SYSTEMIC SCLEROSIS ASSOCIATED WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE**  
*J. Jung, S. Choi, G. Song*
- P.392 SEVERE LIMB ISCHEMIA AFTER VASOPRESSOR THERAPY DUE TO SEPTIC SHOCK FROM PERFORATED ACALCULOUS CHOLECYSTITIS IN A PATIENT WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS**  
*J. Jun, J. Kang, Y. Kim*
- P.393 SYSTEMIC SCLEROSIS SKIN CHANGES AND MULTI-ORGAN INVOLVEMENT AFTER TAXANE TREATMENT**  
*N. Bakhsh, K. Devakandan, Z. Ahmad*
- P.394 SUDDEN CARDIAC DEATH IN TWO PATIENTS WITH RAPIDLY PROGRESSING SYSTEMIC SCLEROSIS**  
*R. Izzo, G. Pellegrino, G. Olivieri, C. Angelelli, K. Stefanantoni, C. Perricone, C. Alessandri, R. Scivo, F. Conti, R. Priori, G. Valesini, V. Riccieri*
- P.395 RARE PULMONARY MANIFESTATIONS OF SYSTEMIC SCLEROSIS – A UNIQUE CASE OF DIAPHRAGMATIC DYSFUNCTION**  
*M. Guerra, M. Silva, S. Neves, B. Samões, D. Fonseca, T. Videira, R. Vieira, J. Abelha-Aleixo, P. Pinto*
- P.396 REFRACTORY DIGITAL ULCERS WITH NECROSIS IN PATIENT WITH OVERLAP SYNDROME – EFFECT OF HYPERBARIC OXYGEN TREATMENT**  
*K. Gheorghe, A. Nordin*
- P.397 DEPLETION OF B-CELLS IN PERIPHERAL BLOOD FOR 10 YEARS IN A PATIENT WITH SYSTEMIC SCLEROSIS, AFTER A SINGLE INFUSION OF RITUXIMAB**  
*L. Garzanova, L. Ananyeva, O. Koneva*
- P.398 SYSTEMIC SCLEROSIS TRIGGERED BY CHIKUNGUNYA FEVER**  
*S. Fontenele, I. Barbosa, B. Parente, J. Monte, M. Moura*
- P.399 GROUP 3 OR COMBINED GROUP 1 AND GROUP 3 PULMONARY HYPERTENSION? THREE CASES WITH THREE SCENARIOS**  
*S. Erol, Z. Onen, O. Ozdemir Kumbasar, T. Sayin, C. Tulunay Kaya*
- P.400 MORPHEA WITH ASSOCIATED SYSTEMIC MANIFESTATIONS: A CASE REPORT**  
*A. Elsonbaty, N. Adel Abbas, N. Fathi*
- P.401 INDUCED SCLERODERMA**  
*V. Babak, M. Starovoytova, O. Desinova, L. Ananieva*
- P.402 SCLEROMXEDEMA WITH MULTIPLE SYSTEMIC INVOLVEMENT: INTRAVENOUS IMMUNOGLOBULIN AS STEROID-SPARING AGENT**  
*W. Choi, S. Kim, K. Lee, H. Kim*
- P.403 WHY THE SCLERODERMIFORM AFFECTATIONS ARE CONSIDERED BORING DISEASES**  
*G. Chalhoub*
- P.404 TOFACITINIB IS A THERAPEUTIC OPTION FOR REFRACTORY EOSINOPHILIC FASCIITIS**  
*X. Cao, J. Zhao, Y. Hou, D. Xu, M. Li, Q. Wang, X. Zeng*
- P.405 ACR/EULAR 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS: AN EXAMPLE OF FEMALE PATIENT WITH EARLY FORM OF SCLERODERMA DIAGNOSED AT CHILDHOOD**  
*K. Bouchalova, P. Horak, D. Pospisilova*
- P.406 DILTIAZEM-INDUCED MYOSITIS IN A PATIENT WITH SYSTEMIC SCLEROSIS**  
*S. Berthier, A. Grandvillemin, B. Nicolas, A. Guilhem, V. Leguy, M. Samson, S. Audia, B. Bonnotte*
- P.407 MALIGNANCY IN A SINGLE CENTER COHORT OF SYSTEMIC SCLEROSIS PATIENTS**  
*A. Balbir Gurman, V. Shataylo, A. Mashiah, N. Schultz, E. Sabbah, Y. Tavor, M. Nahir, K. Dolnikov, N. Finkilstein, Y. Braun-Moskovi*
- P.408 IGG-4 RELATED AORTITIS IN A PATIENT WITH RA-SSC OVERLAP, AN UNEXPECTED COMBINATION**  
*A. Balbir Gurman, Y. Tavor, L. Guralnik, Y. Braun-Moskovi*
- P.409 DRAMATIC SCLERODERMA DEBUT WITH MALIGNANT HYPERTENSION AND RENAL CRISIS**  
*A. Balbir Gurman, G. Milo, S. Assady, R. Dragu, K. Dolnikov, Y. Braun-Moskovi*